Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 1848. Отображено 100.
21-06-2012 дата публикации

Leaving substituent-containing compound, organic semiconductor material, organic semiconductor film containing the material, organic electronic device containing the film, method for producing film-like product, pi-electron conjugated compound and method for producing the pi-electron conjugated compound

Номер: US20120153271A1
Автор: Daisuke Goto, Keiichiro Yutani, Masataka Mohri, Masato Shinoda, Satoshi Yamamoto, Shinji Matsumoto, Takashi Okada, Takuji Kato, Toshiya Sagisaka
Принадлежит: Ricoh Co Ltd

A leaving substituent-containing compound including a partial structure represented by the following General Formula (I): where a pair of X 1 and X 2 or a pair of Y 1 and Y 2 each represent a hydrogen atom; the other pair each represent a group selected from the group consisting of a halogen atom and a substituted or unsubstituted acyloxy group having one or more carbon atoms; a pair of the acyloxy groups represented by the pair of X 1 and X 2 or the pair of Y 1 and Y 2 may be identical or different, or may be bonded together to form a ring; R 1 to R 4 each represent a hydrogen atom or a substituent; and Q 1 and Q 2 each represent a hydrogen atom, a halogen atom or a monovalent organic group, and may be bonded together to form a ring.

Подробнее
Номер записи: 1
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Автор: Bernd Nosse, Gerald Juergen Roth, Heike Neubauer, Joerg Kley, Martin Fleck, Niklas Heine, Thorsten Lehmann-Lintz
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
Номер записи: 2
27-09-2012 дата публикации

Aryloxyanilide imaging agents

Номер: US20120244073A1
Автор: Dennis O' Shea, Harry John Wadsworth
Принадлежит: Individual

The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

Подробнее
Номер записи: 3
26-09-2013 дата публикации

TANNIN INHIBITORS OF HIV

Номер: US20130252909A1
Автор: Kraus George A., Maury Wendy
Принадлежит: UNIVERSITY OF IOWA RESEARCH FOUNDATION

The invention provides a method to prevent or treat HIV-infection with synthetic tannins, and pharmaceutical compositions comprising synthetic tannins. 2. The method of wherein n is 1 claim 1 , m is 1 claim 1 , and p is 1.3. The method of wherein Ris CH.4. The method of wherein Rand Rare G or H.5. The method of wherein Ris G or H.6. The method of wherein Ris H or G and Ris H or G.7. The method of wherein Rand Rare H.8. The method of wherein Ris H.11. The method of wherein n is 0.13. The method of wherein Ror Ris CH.14. The method of wherein Rand/or Rare G.15. The method of wherein n is 1 claim 1 , m is 0 and p is 0.17. The method of wherein Rand/or Rare G.18. The method of wherein Ror Rare CH.20. The method of wherein Ris G.21. The method of wherein Rand Rare H.23. The method of wherein Rand/or Rare G.24. The method of wherein Ris H. This application claims priority of U.S. provisional patent application Ser. No. 61/614,792, filed Mar. 23, 2012, which is incorporated by reference herein.This invention was made with the support of the National Institutes of Health under Grant No. P50 AT004155. The U.S. Government has certain rights in the invention.With more than 33 million people currently infected with human immunodeficiency virus (HIV) and 2 million additional individuals infected each year, there is a worldwide imperative to reduce transmission of this deadly virus. Worldwide, sexual transmission is the primary route of new virus infections. Strategies to reduce spread of this virus can be achieved by reducing virus loads in currently infected individuals (and thereby reducing levels of virus exposure) and/or by blocking sexual transmission by the use of effective and safe microbicides.Clinically useful anti-retrovirals target a number of steps of the HIV-1 life cycle including co-receptor (CCR5) binding, virus membrane/cellular membrane fusion, reverse transcription, integration and proteolytic processing. See, e.g. Martins et al., 15, 1083 (2008). Combination ...

Подробнее
Номер записи: 4
03-10-2013 дата публикации

PHARMACEUTICAL AND FOOD COMPOSITIONS FOR PREVENTING OR TREATING DIABETES OR OBESITY

Номер: US20130261174A1
Автор: Han Se Jong, HARI DATTA Bhattarai, JO Dong-Gyu, Kang Pil-Sung, Kim Doc Kyu, Kim Il Chan, KIM Jung Eun, KIM Keun-Sik, Kim Sung Jin, Kim Tai Kyoung, LEE Cheolsoon, Lee Hyoung Seok, LEE Pyung Cheon, OH Hyun Cheol, Park Ha Ju, Park Heeyong, PARK Mi Ra, PARK Yu-Kyung, Yim Joung Han
Принадлежит: KOREA OCEAN RESEARCH AND DEVELOPMENT INSTITUTE

The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the . The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity. 926.-. (canceled) The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Antarctic lichensAntarctic lichens are known to produce unique secondary metabolites different from those produced by higher plants (Ingolfsdottir, K., 61:729, 2002). The secondary metabolites produced by these lichens mostly belong to the chemical classes of depsides, depsidones, and dibenzofurans, and these compounds are supposed to be associated with the low growth rate of lichens (Kumar, K. C. S. et al., 62:817, 1999; Huneck, S., 86:559, 1999). In addition, the various biological activities of lichens, including antibiotic, antimycobacterial, antiviral, pain-killing, and antipyretic activities, and so on were found in screening processes (Ingolfsdottir, K., 61:729, 2002; Kumar, K. C. S. et al., 62:817, 1999). Thus, Interest has grown in the development of medical drugs using lichen metabolites.Meanwhile, diabetes is metabolic disorder symptom, including hyperglycemia, which results from defects in insulin action, insulin secretion, or both. Also, ...

Подробнее
Номер записи: 5
07-11-2013 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20130296373A1
Автор: Bravo-Altamirano Karla, Li Fangzheng, Meyer Kevin G., Nugent Benjamin M., Owen W. John, Renga James M., Wilmot Jeremy, Yao Chenglin
Принадлежит: DOW AGROSCIENCES LLC

The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are independently chosen from H or C(O)R.3. The compound according to claim 2 , wherein Ris independently chosen from H claim 2 , alkyl claim 2 , alkenyl claim 2 , aryl claim 2 , heterocyclyl claim 2 , silyl claim 2 , —C(O)R claim 2 , each substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 3 , wherein Ris independently phenyl or cyclohexyl.5. The compound according to claim 4 , wherein Ris alkyl or aryl substituted with 0 claim 4 , 1 claim 4 , or multiple R.6. The compound according to claim 5 , wherein Ris alkoxy or benzyloxy substituted with 0 claim 5 , 1 claim 5 , or multiple R.7. The compound according to claim 6 , wherein Ris hydrogen or alkyl.8. The compound according to claim 1 , wherein X is H and Y is Q.10. The compound according to claim 9 , wherein Ris independently chosen from alkyl claim 9 , aryl claim 9 , or —C(O)R claim 9 , each substituted with 0 claim 9 , 1 or multiple R.11. The compound according to claim 10 , wherein Ris phenyl.12. The compound according to claim 11 , wherein Ris alkyl substituted with 0 claim 11 , 1 claim 11 , or multiple R.13. The compound according to claim 12 , wherein Ris alkyl claim 12 , aryl claim 12 , alkoxy claim 12 , or halo.14. A composition for the control of a fungal pathogen including at least one of the compounds according to and a phytologically acceptable carrier material.16Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The composition according to claim claim 1 , 14 wherein the plant pathogen is at least one ...

Подробнее
Номер записи: 6
07-11-2013 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20130296375A1
Автор: Boebel Timothy A., Bravo-Altamirano Karla, Graupner Paul R., Heemstra Ronald J., Herrick Jessica, Li Fangzheng, Meyer Kevin G., Nugent Benjamin M., Owen W. John, Renga James M., Wang Nick X., Yao Chenglin
Принадлежит: DOW AGROSCIENCES LLC

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A compound according to claim 1 , wherein:{'sub': '6', 'wherein, R is H, C(O)R;'}{'sub': 1', '6, 'Ris H, C(O)R;'}{'sub': 2', '5, 'Ris independently or separately H, alkyl, alkenyl, aryl, each substituted with 0, 1 or multiple R;'}{'sub': '3', 'Ris independently or separately H, methyl;'}{'sub': '5', 'Ris alkyl, alkoxy, halo, haloalkyl, or aryl; and'}{'sub': '6', 'Ris alkoxy, benzyloxy.'}5Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 4 , wherein the plant pathogen is least one pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 4 , Wheat Brown Rust () claim 4 , Stripe Rust () claim 4 , Scab of Apple () claim 4 , Blister Smut of Maize () claim 4 , Powdery Mildew of Grapevine () claim 4 , Barley scald () claim 4 , Blast of Rice () claim 4 , Downy Mildew of Cucurbits () claim 4 , Rust of Soybean () claim 4 , Glume Blotch of Wheat () claim 4 , Powdery Mildew of Wheat (f. sp. ) claim 4 , Powdery Mildew of Barley (f. sp. ) claim 4 , Powdery Mildew of Cucurbits () claim 4 , Anthracnose of Cucurbits () claim 4 , Leaf Spot of Beet () claim 4 , Early Blight of Tomato () claim 4 , and Net Blotch of Barley ().6Septoria triticiPuccinia triticinaPhakopsora pachyrhizi. The composition according to claim 5 , wherein the fungal pathogen is at least one of Leaf Blotch of Wheat () claim 5 , Wheat Brown Rust () claim 5 , and Rust of Soybean ().8. The method according to claim 7 , wherein the compound is applied in a mixture with at least one additional compound selected from the group ...

Подробнее
Номер записи: 7
12-12-2013 дата публикации

GLP-1 POTENTIATORS FROM HEDYCHIUM CORONARIUM AND THEIR APPLICATIONS

Номер: US20130331323A1
Автор: Chen Hui-Ling, HUANG Jiann-Jyh, King K-Lim, Lee Shoei-Sheng, WU REY-YUH, Wu Yu-Yuan
Принадлежит: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

A compound for controlling blood glucose level has a structure shown in Formula I: 5. A method for controlling blood glucose level claim 1 , comprising administering to a subject in need thereof the compound of .6. The method of claim 5 , further comprising administering to the subject a glucagon-like peptide-1 (GLP-1) receptor ligand to the subject.7. The method of claim 6 , wherein the GLP-1 receptor ligand is GLP-1 or exendin-4.8. The method of claim 6 , wherein the compound and the GLP-1 receptor ligand are administered together.10. The method of claim 9 , wherein the compound has a structure of 1A.11. The method of claim 9 , wherein the compound has a structure of 1B. 1. Technical Field of the InventionThe present invention relates to new uses of compounds, particularly a diterpenoid Galanal B, in the regulation of blood glucose levels.2. BackgroundGlucagon-like peptide-1 (GLP-1) analogues are a new class of hypoglycemic agents. GLP-1 is a member of the incretin family, which comprises gastrointestinal hormones that help control blood glucose levels after meals. GLP-1 exerts its functions by specific binding to GLP-1 receptor. GLP-1 receptor (GLP-1R) is widely distributed. In addition to pancreatic tissue, GLP-1 receptor is also distributed in the brain, lung, heart, kidney, etc. The wide distribution of this receptor contributes to the wide range of its functions.GLP-1 bind specifically to the GLP-1 receptor on the pancreatic beta cells. Activation of GLP-1R leads to stimulation of the adenylyl cyclase pathway, which eventually leads to increased insulin synthesis and release. In addition to the increased insulin synthesis and release, GLP-1 binding to its receptor also inhibits the production of glucagon and maintains constant levels of blood glucose after meals. Furthermore, GLP-1 also has a neuron regulatory function, which can delay gastric emptying and reduce appetite. At the same time, the hypoglycemic effect of GLP-1 is self-limiting and will not result ...

Подробнее
Номер записи: 8
20-02-2014 дата публикации

INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES

Номер: US20140051678A1
Автор: Clement-Schatlo Virginie, CRIBIU Riccardo, Fessard Thomas
Принадлежит: STEMERGIE BIOTECHNOLOGY SA

The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and/or preventing cancers presenting tumor-initiating cells. (Formula I) (I) 135.-. (canceled)37. The compound of claim 36 , wherein Ar is selected from (C5-C6)aromatic ring or (C5-C6)heteroaromatic ring where one or more of the carbon atoms in the ring system are replaced by heteroatoms selected from the group consisting of O claim 36 , S claim 36 , and N.38. The compound of claim 37 , wherein Ar is (C5-C6)aromatic ring.39. The compound of claim 36 , wherein A1 is —(C═O)—.40. The compound of claim 36 , wherein Aand Aare —C(═O)—.41. The compound of claim 36 , wherein Band Bare independently of each other selected from —O— claim 36 , —S— claim 36 , —NH— claim 36 , —CH— claim 36 , with the proviso that at least one of Band Bis not —O—.42. The compound of claim 36 , wherein Rand Rform together a (C3-C10)cycloalkyl or (C3-C10)heterocycloalkyl substituted by Rand R claim 36 , where Rand Rare independently of each other selected from —H claim 36 , —(C1-C10)alkyl claim 36 , —(C1-C10)alkenyl claim 36 , —(C1-C10)alkynyl claim 36 , mono or polyfluorinated (C1-C10)alkyl claim 36 , -aryl claim 36 , —OH claim 36 , —O—(C1-C10)alkyl claim 36 , —O—aryl claim 36 , —O(C═O)—(C1-C10)alkyl claim 36 , —O(C═O)-aryl claim 36 , and halogen.43. The compound of claim 36 , wherein R claim 36 , Rand Rare —H.44. The compound of claim 36 , wherein Rand Rform a bond together.45. The compound of claim 44 , wherein Aand Aare —C(═O)— and Ris H.46 ...

Подробнее
Номер записи: 9
27-02-2014 дата публикации

2,2'-Binaphthalene Ester Chiral Dopants for Cholesteric Liquid Crystal Displays

Номер: US20140054498A1
Автор: Donald R. Diehl, Erica N. Montbach
Принадлежит: Kent Displays Inc, KENT STATE UNIVERSITY

A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C═O)R9, —(C═O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Подробнее
Номер записи: 10
20-03-2014 дата публикации

IRE-1alpha INHIBITORS

Номер: US20140080832A1
Автор: Flynn Gary A., LONERGAN David Gregory, PALLAI Peter V., PATTERSON John Bruce, ZENG Qingping
Принадлежит: MANNKIND CORPORATION

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. 2. The compound of claim 1 , wherein the compound is represented by structural formula (E).3. The compound of claim 1 , wherein the compound is represented by structural formula (X).8. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a compound of or a pharmaceutically acceptable salt thereof; and'}a pharmaceutically acceptable carrier.9. A method of inhibiting IRE-1α activity claim 1 , comprising administering to a subject a compound of or a pharmaceutically acceptable salt of the compound.10. The method of claim 1 , wherein the compound is a compound of .11. The method of claim 1 , wherein the compound is a compound of .12. The method of claim 1 , wherein the compound is a compound of .13. The method of claim 1 , wherein the compound is a compound of .14. The method of claim 1 , wherein the compound is a compound of15. The method of claim 1 , wherein the compound is a compound of .16. The method of wherein cells of the subject have an activated unfolded protein response.17. The method of claim 9 , wherein the subject has cancer.18. The method of claim 17 , wherein the cancer is myeloma.19. The method of claim 9 , further comprising administering to the subject an agent that induces or up-regulates IRE-1α expression.20. The method of claim 9 , further comprising administering to the subject a biotherapeutic agent claim 9 , a chemotherapeutic agent claim 9 , radiation claim 9 , or a proteasome inhibitor. This application is a division of Ser. No. 12/941,530 filed on Nov. 8, 2010, which is a continuation of Ser. No. 12/135,571 filed on Jun. 9, 2008, now U.S. Pat. No. 7,858,666, which claims the benefit of Ser. No. 60/942,743 filed Jun. 8, 2007. ...

Подробнее
Номер записи: 11
07-01-2016 дата публикации

NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES

Номер: US20160002157A1
Автор: Xu Lina, Yu Chongxi
Принадлежит:

One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. 2. A pharmaceutical composition comprising a high penetration prodrug according to ; a compound comprising a structure selected from the group consisting of Structure NSAID-1 claim 1 , Structure NSAID-2 claim 1 , Structure NSAID-3 claim 1 , Structure NSAID-4 claim 1 , Structure NSAID-5 claim 1 , Structure NSAID-6 claim 1 , Structure NSAID-7 claim 1 , Structure NSAID-8 claim 1 , Structure NSAID-9 claim 1 , Structure NSAID-10 claim 1 , Structure NSAID-11 claim 1 , Structure NSAID-12 claim 1 , and Structure NSAID-13; an aromatic-L-amino-acid decarboxylase inhibitor selected from the group consisting of carbidopa claim 1 , benserazide claim 1 , difluromethyldopa claim 1 , and α-methyldopa; a catechol-O-methyl transferase inhibitor selected from the group consisting of entacapone and tolcapone; and a pharmaceutically acceptable carrier.3. The pharmaceutical composition according to claim 2 , the pharmaceutically acceptable carrier being selected from the group consisting of alcohol claim 2 , acetone claim 2 , ester claim 2 , cellulose claim 2 , mannitol claim 2 , croscarmellose sodium claim 2 , vegetable oil claim 2 , ...

Подробнее
Номер записи: 12
04-01-2018 дата публикации

MACROCYCLIC PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY

Номер: US20180002319A1
Автор: ARNOLD Amela, Bravo-Altamirano Karla, Daeuble, DeLorbe Johnathan E., Herrick Jessica, Jones David M., LaLonde Rebecca Lyn K.C., Li Fangzheng, Meyer Kevin G., Renga James M., SR. John F., Wilmot Jeremy, Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 2 , wherein Ris selected from the group consisting of hydrogen claim 2 , alkyl claim 2 , alkenyl claim 2 , and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 claim 2 , or multiple R.4. (canceled)5. The compound according to claim 2 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 2 , alkyl claim 2 , alkenyl claim 2 , and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 claim 2 , or multiple R.6. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.7. The compound according to claim 6 , wherein Ris selected from the group consisting of hydrogen claim 6 , alkyl claim 6 , alkenyl claim 6 , and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.8. (canceled)9. The compound according to claim 6 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 6 , alkyl claim 6 , alkenyl claim 6 , and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.10. The compound according to claim 1 , wherein X is hydrogen and Y is Q.11. The compound according to claim 10 , wherein Ris alkoxy.12. The compound according to claim 11 , wherein Ris hydrogen.13. The compound according to claim 12 , wherein Ris selected from the group consisting of hydrogen claim 12 , alkyl claim 12 , alkenyl claim 12 , and aryl claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. (canceled)15. The compound according to claim 12 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 12 , alkyl claim 12 , alkenyl claim 12 , and aryl claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.16. The compound according to claim 11 , ...

Подробнее
Номер записи: 13
04-01-2018 дата публикации

USE OF MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20180002320A1
Автор: ARNOLD Amela, Bravo-Altamirano Karla, Daeuble, DeLorbe Johnathan E., Herrick Jessica, Jones David M., LaLonde Rebecca Lyn K.C., Li Fangzheng, Meyer Kevin G., Renga James M., SR. John F., Wilmot Jeremy, Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A composition according to claim 1 , wherein X is hydrogen and Y is Q.3. A composition according to claim 2 , wherein Ris alkoxy.4. A composition according to claim 3 , wherein Ris hydrogen.5. A composition according to claim 4 , wherein Ris selected from the group consisting of hydrogen claim 4 , alkyl claim 4 , alkenyl claim 4 , and aryl claim 4 , each optionally substituted with 0 claim 4 , 1 claim 4 , or multiple R.6. (canceled)7. A composition according to claim 4 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 4 , alkyl claim 4 , alkenyl claim 4 , and aryl claim 4 , each optionally substituted with 0 claim 4 , 1 claim 4 , or multiple R.8. A composition according to claim 3 , wherein Ris selected from the group consisting of —C(O)Rand —CHOC(O)R.9. A composition according to claim 8 , wherein Ris alkyl claim 8 , optionally substituted with 0 claim 8 , 1 claim 8 , or multiple R.10. A composition according to claim 9 , wherein Ris selected from the group consisting of hydrogen claim 9 , alkyl claim 9 , alkenyl claim 9 , and aryl claim 9 , each optionally substituted with 0 claim 9 , 1 claim 9 , or multiple R.11. (canceled)12. A composition according to claim 9 , wherein Ris independently selected for Rand Rfrom the group consisting of hydrogen claim 9 , alkyl claim 9 , alkenyl claim 9 , and aryl claim 9 , each optionally substituted with 0 claim 9 , 1 claim 9 , or multiple R.13. A composition according to claim 12 , wherein Ris selected from the group consisting of —CH claim 12 , —CH(CH) claim 12 , and —CHOCHCH.14. A composition for the control of a fungal pathogen including at least one of the compositions of and a phytologically acceptable carrier material.15. A composition for the control of a fungal pathogen including at least one of the compositions of and a phytologically acceptable carrier material.16. (canceled)17. A ...

Подробнее
Номер записи: 14
13-01-2022 дата публикации

Salt, acid generator, resist composition and method for producing resist pattern

Номер: US20220011667A1
Автор: Katsuhiro Komuro, Koji Ichikawa
Принадлежит: Sumitomo Chemical Co Ltd

Disclosed are a salt represented by formula (I), an acid generator and a resist composition: wherein R 1 , R 2 and R 3 each represent I or F, R 4 , R 5 , R 6 , R 7 , R 8 and R 9 each represent a halogen atom, a hydroxy group, a haloalkyl group or a hydrocarbon group, X 1 , X 2 and X 3 each represent O or S, m1 and m7 represent an integer of 0 to 5, m2, m3, m4, m5, m6, m8 and m9 represent an integer of 0 to 4, in which 0≤m1+m7≤5, 0≤m2+m8≤4, 0≤m3+m9≤4, at least one of m1, m2, m3 represents an integer of 1 or more, X 4 represents a single bond, —CH 2 —, —O—, —S—, —CO—, —SO— or —SO 2 —, and AI − represents an organic anion.

Подробнее
Номер записи: 15
14-01-2016 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20160007601A1
Автор: Boebel Timothy A., Bravo-Altamirano Karla, Daeuble John F., Lu Yu, Meyer Kevin G., Nugent Benjamin M., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.4. The compound according to claim 1 , wherein X is hydrogen and Y is Q.5. The compound according to claim 4 , wherein Ris hydrogen.6. The compound according to claim 4 , wherein Ris —C(O)Ror —CHOC(O)R.7. The compound according to claim 6 , wherein Ris alkyl or alkoxy claim 6 , each optionally substituted with 0 claim 6 , 1 claim 6 , or multiple R.8. The compound according to claim 7 , wherein Ris chosen from —CH claim 7 , —CH(CH) claim 7 , —CHOCHCH claim 7 , or —CHCHOCH.9. A composition for the control of a fungal pathogen including at least one of the compounds of and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 1 , a second fungicide claim 1 , an insecticide claim 1 , a nematocides claim 1 , a miticide claim 1 , an arthropodicide claim 1 , a bactericide.10. The composition for the control of a fungal pathogen according to claim 9 , wherein the at least one additional compound is at least one phytologically acceptable carrier material.11Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 9 , wherein the fungal pathogen is at least one pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 9 , Wheat Brown Rust () claim 9 , Stripe Rust () claim 9 , Scab of Apple () claim 9 , Blister Smut of Maize () claim 9 , Powdery Mildew of Grapevine () claim 9 , Barley Scald () claim 9 , Blast of ...

Подробнее
Номер записи: 16
14-01-2016 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20160007602A1
Автор: Bravo-Altamirano Karla, Daeuble John F., DeKorver Kyle A., DeLorbe Johnathan E., Heemstra Ron J., Meyer Kevin G., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 2 , wherein Ris alkyl or aryl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 2 , wherein Ris hydrogen or alkyl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.5. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.6. The compound according to claim 5 , wherein Ris alkyl or aryl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.7. The compound according to claim 5 , wherein Ris hydrogen or alkyl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.8. The compound according to claim 1 , wherein X is hydrogen and Y is Q.9. The compound according to claim 8 , wherein Ris alkyl or aryl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.10. The compound according to claim 8 , wherein Ris hydrogen or alkyl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.11. The compound according to claim 9 , wherein Ris hydrogen.12. The compound according to claim 9 , wherein Ris —C(O)Ror —CHOC(O)R.13. The compound according to claim 12 , wherein Ris alkyl or alkoxy claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. The compound according to claim 13 , wherein Ris —CH claim 13 , —CH(CH) claim 13 , —CHOCHCH claim 13 , or —CHCHOCH.15. A composition for the control of a fungal pathogen including at least one of the compounds of Formula I and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 13 , a second fungicide claim 13 , an insecticide claim 13 , a nematocide claim 13 , a miticide claim 13 , an arthropodicide claim 13 , and a bactericide.16. The composition according to claim 15 , wherein the least one ...

Подробнее
Номер записи: 17
14-01-2021 дата публикации

COMPOUNDS AND METHODS FOR TREATING FIBROSIS OR CANCER

Номер: US20210009551A1
Автор: Backes Bradley J., Chapman Harold A., Wei Ying
Принадлежит:

Provided herein, inter alia, are methods and compounds for treating a pulmonary disease, fibrosis, or cancer. 3. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.4. (canceled)5. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.6. (canceled)7. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.8. (canceled)9. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.10. (canceled)11. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.12. (canceled)13. The compound of claim 1 , wherein Ris —NH claim 1 , —OH claim 1 , or substituted or unsubstituted heteroalkyl.14. (canceled)17. (canceled)18. (canceled)19. (canceled)20. The compound of claim 1 , wherein Ris independently —COOR claim 1 , —NRC(O)OR claim 1 , or —C(O)R.2128.-. (canceled)29. The compound of claim 1 , wherein Ris independently hydrogen.30. The compound of claim 1 , wherein Ris independently hydrogen.31. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable excipient.32. A method of reducing the level of activity of zinc finger protein Snail1 in a subject claim 1 , said method comprising administering an effective amount of a compound of to the subject.33. A method of reducing the level of activity of Lysyl oxidase homolog 2 (LOXL2) in a subject claim 1 , said method comprising administering an effective amount of a compound of to the subject.34. A method of inhibiting collagen cross-linking in a subject claim 1 , said method comprising administering an effective amount of a compound of to the subject.35. A method of treating fibrosis claim 1 , said method comprising administering to a subject in need thereof an effective amount of a compound of .36. (canceled)37. (canceled)38. A method ...

Подробнее
Номер записи: 18
10-01-2019 дата публикации

BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA

Номер: US20190010400A1
Автор: ADLEM Kevin, NAMUTEBI Mariam, Parri Owain Llyr, Saxton Patricia Eileen, SNOW Benjamin, TUFFIN Rachel
Принадлежит: Merck Patent GmBH

The invention relates to bimesogenic compounds of formula I 2. Bimesogenic compounds according to claim 1 , characterized in that MGand MGare independently of each other selected of partial formula II{'br': None, 'sup': 11', '11', '12, 'sub': 'k', '-A-(Z-A)- \u2003\u2003II'}wherein{'sup': '11', 'sub': 2', '2', '2', '2', '2', '2', '2', '4', '2', '2, 'Zare, independently of each other in each occurrence, a single bond, —COO—, —OCO—, —O—CO—O—, —OCH—, —CHO—, —OCF—, —CF)—, —CHCH—, —(CH)—, —CFCF—, —CH═CH—, —CF═CF—, —CH═CH—COO—, —OCO—CH═CH— or —C≡C—, optionally substituted with one or more of F, S and/or Si,'}{'sup': 11', '12, 'sub': '2', 'Aand Aare each independently in each occurrence 1,4-phenylene, wherein in addition one or more CH groups may be replaced by N, trans-1,4-cyclo-hexylene in which, in addition, one or two non-adjacent CHgroups may be replaced by O and/or S, 1,4-cyclohexenylene, 1,4-bicyclo-(2,2,2)-octylene, piperidine-1,4-diyl, naphthalene-2,6-diyl, decahydro-naphthalene-2,6-diyl, 1,2,3,4-tetrahydro-naphthalene-2,6-diyl, cyclobutane-1,3-diyl, spiro[3.3]heptane-2,6-diyl or dispiro[3.1.3.1] decane-2,8-diyl, it being possible for all these groups to be unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl, CN or alkyl, alkoxy, alkylcarbonyl or alkoxycarbonyl groups with 1 to 7 C atoms, wherein one or more H atoms may be substituted by F or Cl, and'}k is 0, 1, 2, 3 or 4.3. Bimesogenic compounds according to claim 1 , characterized in that MGand MGare independently of one another selected from the group of formulae II-1 to II-26{'br': None, '-Phe-Z-Phe- \u2003\u2003II-1'}{'br': None, '-Phe-Z-Cyc- \u2003\u2003II-2'}{'br': None, '-Cyc-Z-Cyc- \u2003\u2003II-3'}{'br': None, '-Phe-Z-PheL- \u2003\u2003II-4'}{'br': None, '-PheL-Z-Phe- \u2003\u2003II-5'}{'br': None, '-PheL-Z-Cyc- \u2003\u2003II-6'}{'br': None, '-PheL-Z-PheL- \u2003\u2003II-7'}{'br': None, '-Phe-Z-Phe-Z-Phe- \u2003\u2003II-8'}{'br': None, '-Phe-Z-Phe-Z-Cyc- \u2003\u2003II-9'}{'br': None, '-Phe- ...

Подробнее
Номер записи: 19
17-02-2022 дата публикации

CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING

Номер: US20220047725A1
Автор: Eilon Tal, Green Ori, Hananya Nir, Satchi-Fainaro Ronit, Shabat Doron
Принадлежит:

The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging. 3. The conjugate of claim 2 , wherein Rand Rtogether with the carbon atom to which they are attached form adamantyl.4. The conjugate of claim 2 , wherein Xis —(CH)-para-phenylene; and Xis —C(O)—.5. The conjugate of claim 1 , wherein:{'sup': '1', 'sub': 1', '8, 'Ris a linear or branched (C-C)alkyl;'}{'sup': 2', '3, 'Rand Rtogether with the carbon atom to which they are attached form a fused, spiro or bridged polycyclic ring;'}{'sup': 7', '8', '9', '7', '8', '9, 'sub': '2', 'at least one of R, Rand Ris H, and the other of R, Rand Reach independently is an electron acceptor group selected from the group consisting of halogen, —NOand —CN; and'}{'sub': 1', '2', '1', '1', '18', '6', '14', '1', '18', '6', '14', '2', '2', '2', '2', '2', '3', '6', '10', '1', '4', '6', '10', '1', '4', '1', '18', '1', '8', '6', '10', '6', '10', '2, 'X is a linker of the formula —X—X—, wherein Xis (C-C)alkylene, (C-C)arylene-diyl, or (C-C)alkylene-(C-C)arylene-diyl, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —COH, —COOH, —OCOOH, —OCONH, —CN, —NO, —SH, —OH, —NH, —CONH, —SOH, —SOH, —S(═O)H, (C-C)aryl, (C-C)alkylene-(C-C)aryl, heteroaryl, and (C-C)alkylene-heteroaryl, and said (C-C)alkylene being further optionally interrupted by one or more identical or different heteroatoms selected from the group consisting of S, O and N, and/or at least one group each independently selected from the group consisting of —NH—CO—, —CO—NH—, —N(C-Calkyl)-, —N(C-Caryl)-, (C-C)arylene-diyl, and heteroarylenediyl; and Xis —C(O)—.'}6. The conjugate of claim 5 , wherein Ris methyl; Rand Rtogether with the carbon atom to which they are attached form adamantly; Xis —(CH)-para-phenylene; ...

Подробнее
Номер записи: 20
01-05-2014 дата публикации

2,2'-Binaphthalene Ester Chiral Dopants for Cholesteric Liquid Crystal Displays

Номер: US20140117284A1
Автор: Donald R. Diehl, Erica N. Montbach
Принадлежит: Kent Displays Inc, KENT STATE UNIVERSITY

A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C═O)R9, —(C═O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R4 is hydrogen, alkyl, aryl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R5, R6, R7, and R8 are independently hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted, or combine with each other, or R5 can combine with R4 to form a carbocyclic or heterocyclic ring; R9 and R10 are independently alkyl, alkoxy, aryl, naphthyl, styryl, alkenyl, cycloalkyl, alkoxyaryl, cycloalkoxy, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4.

Подробнее
Номер записи: 21
19-02-2015 дата публикации

Method for preparing cyclopropane derivatives

Номер: US20150051394A1
Автор: E.J.N. Remy LITJENS, Eleonora KISS, Erwin Blomsma, Serge DE BRUIJN
Принадлежит: Aratana Therapeutics NV

The present invention relates to the preparation of cyclopropane derivatives, in particular 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-4,8-dihydro-1H-purin-6-one, especially via the [(1S,7R)-4-phenyl-3,5-dioxabicyclo[5.1.0]octan-1-yl]methanol intermediate.

Подробнее
Номер записи: 22
03-03-2022 дата публикации

Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases

Номер: US20220064157A1
Автор: Chongxi Yu, Lina Xu
Принадлежит: Techfields Pharma Co Ltd

One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Подробнее
Номер записи: 23
25-02-2016 дата публикации

LIGHT UP-CONVERSION LUMINESCENT SUBSTANCE

Номер: US20160053168A1
Автор: KAMADA Kenji, Kobayashi Kenji
Принадлежит: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY

[Problem] To provide a novel light up-conversion organic luminescent substance having a high light up-conversion efficiency. 5. The light up-conversion luminescent substance according to claim 1 , wherein group Xand group Xof the general formula (1) each independently represent a straight-chain alkylene group with a carbon number of 5 to 10 claim 1 , optionally having at least one bond selected from the group consisting of an ether bond claim 1 , an ester bond claim 1 , an amide bond claim 1 , and a sulfide bond.6. A light up-conversion material comprising the light up-conversion luminescent substance according to claim 1 , and a photosensitizer.7. The light up-conversion material according to claim 6 , further comprising a solvent claim 6 , a resin claim 6 , or a glass.8. A method of converting a light wavelength claim 6 , comprising irradiating the light up-conversion material according to with light to cause emission of light having a shorter wavelength than the radiating light. The present invention relates to a light up-conversion luminescent substance that converts long-wavelength light to short-wavelength light, and a light up-conversion material containing the same.In the related art, light up-conversion luminescent substances that convert long-wavelength light to short-wavelength light are known. The light up-conversion luminescent substances and inorganic light up-conversion luminescent substances in which a rare-earth element or the like is used are known. The inorganic light up-conversion luminescent substances have been applied, for example, to IR cards that convert infrared laser light to visible light, and have already been brought into practical use.On the other hand, when inorganic light up-conversion luminescent substances in which an organic compound is used, it is known that an intense and broad absorption spectrum of the organic compound is used to enable light up-conversion with broader wavelengths and lower incident power compared with the ...

Подробнее
Номер записи: 24
25-02-2021 дата публикации

TREPROSTINIL PRODRUGS

Номер: US20210054009A1
Автор: Batra Hitesh, GUO LIANG, Phares Kenneth Robert
Принадлежит: United Therapeutics Corporation

Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs. 146-. (canceled)48. A pharmaceutical composition claim 47 , comprising (A) an effective amount of the compound of and (B) a pharmaceutically acceptable carrier.49. A method of treating pulmonary hypertension comprising administering to a subject in need thereof the composition of .50. The method of claim 49 , wherein the composition is administered orally.51. The method of claim 49 , wherein the subject has detectable treprostinil plasma levels for at least 24 hours following said administration.52. The method of claim 49 , wherein the composition is administered by an injection.53. The method of claim 52 , wherein the administration is performed subcutaneously.54. The method of claim 53 , wherein said administration is continuous subcutaneous administration.55. The method of claim 52 , wherein said administration results in no or less pain at a site of the injection compared to administering treprostinil.56. The method of claim 49 , wherein the subject is a human being.57. The method of claim 49 , wherein upon said administration said compound converts to a metabolic product claim 49 , which consists essentially of treprostinil.58. The method of claim 57 , wherein said metabolic product consists of treprostinil.61. The method of claim 60 , wherein Ris C-Calkylene and each of Rand Rare H.62. The method of claim 49 , wherein Ris —C(O)—CHR—N(R) claim 49 , wherein Ris the side group of an amino acid.63. The method of claim 62 , wherein the amino acid is alanine claim 62 , valine or glycine.64. The method of claim 49 , wherein Ris a third drug moiety linked to the compound via an ester.65. The method of claim 49 , wherein the second drug moiety is a pain relief drug moiety.66. The method of claim 49 , wherein the second drug moiety is a nonsteroidal anti-inflammatory drug moiety.67. The method of claim 66 , wherein the second drug moiety is selected from the ...

Подробнее
Номер записи: 25
20-02-2020 дата публикации

Flash and Glow 1,2-Dioxetanes

Номер: US20200056222A1
Автор: Edwards Brooks, Mihali Albana, Wang Zhixian
Принадлежит:

Compounds having chemiluminescent flash and glow properties. Also disclosed are methods using the compounds to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Also disclosed are kits relating to these compounds. 216.-. (canceled)17. The compound of claim 1 , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 25° C. which reaches a maximum in less than about 15 minutes.18. The compound of claim 17 , wherein the generation of light reaches a maximum in less than about 10 minutes.19. The compound of claim 17 , wherein the generation of light reaches a maximum in less than about 5 minutes.20. The compound of claim 1 , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 37° C. which reaches a maximum in less than about 15 minutes.21. The compound of claim 20 , wherein the generation of light reaches a maximum in less than about 10 minutes.22. The compound of claim 20 , wherein the generation of light reaches a maximum in less than about 5 minutes.24. A method for generating light claim 20 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) providing the compound of ;'}(b) providing an enzyme complex comprising an enzyme moiety which is capable of cleaving the compound;(c) contacting the enzyme complex with the compound to form a reaction mixture; and,(d) allowing the reaction mixture to generate light.2584.-. (canceled)86. An assay method for determining the presence and/or amount of an enzyme in a sample claim 20 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(a) providing the compound of ;'}(b) providing a sample suspected of comprising the enzyme which is capable of cleaving the compound so that it decomposes and generates light;(c) contacting the sample with the compound to form a reaction mixture; and,(d) detecting the light generated by the reaction mixture after addition of the ...

Подробнее
Номер записи: 26
27-02-2020 дата публикации

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Номер: US20200062726A1
Автор: BECKER Cyrus K., Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит: CORSAIR PHARMA, INC.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 181-. (canceled)83. The compound of claim 82 , wherein Ris Pand Ris H.84. The compound of claim 82 , wherein Ris H and Ris P.85. The compound of claim 82 , wherein Ris Pand Ris P.88. The compound of claim 82 , wherein each of Rto Ris H.89. The compound of claim 82 , wherein at least one of Rto Ris deuterium.90. The compound of claim 82 , wherein Z is —OH claim 82 , —OR claim 82 , —N(R)Ror P.91. The compound of claim 82 , wherein Z is P.92. The compound of claim 82 , wherein Z is —OH.93. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipients.94. The pharmaceutical composition of claim 93 , which is formulated for transdermal delivery claim 93 , optionally via a patch.95. A method of treating pulmonary hypertension claim 82 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.96. The method of claim 95 , wherein the pulmonary hypertension is pulmonary arterial hypertension.97. The method of claim 95 , wherein the compound is administered orally claim 95 , topically or parenterally.98. The method of claim 97 , wherein the compound is administered transdermally claim 97 , optionally via a patch.99. The method of claim 95 , further comprising administering an additional therapeutic agent.100. The method of claim 99 , wherein the additional therapeutic agent is selected from the group consisting of vasoactive agents claim 99 , diuretics claim 99 , anticoagulants and cardiac glycosides. This application is ...

Подробнее
Номер записи: 27
08-03-2018 дата публикации

Salt and photoresist composition containing the same

Номер: US20180065925A1
Автор: Hiromu Sakamoto, Koji Ichikawa, Mutsuko Higo
Принадлежит: Sumitomo Chemical Co Ltd

A salt represented by formula (I): wherein R 1 and R 2 independently each represent a C6-C18 unsubstituted or substituted aromatic hydrocarbon group, X 1 represents a C1-C12 divalent aliphatic saturated hydrocarbon group in which a methylene group can be replaced by an oxygen atom or a carbonyl group, and A − represents an organic anion.

Подробнее
Номер записи: 28
23-03-2017 дата публикации

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Номер: US20170081303A1
Автор: BECKER Cyrus K., Pfister Jürg R., Rescourio Gwenaella, Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит:

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 181-. (canceled)83. The compound of claim 82 , wherein Ris H and Ris P.84. The compound of claim 82 , wherein Ris Pand Ris H.85. The compound of claim 82 , wherein Ris Pand Ris P.86. The compound of claim 82 , wherein Rand Rare each H.87. The compound of claim 82 , wherein each of Rto Ris H.88. The compound of claim 82 , wherein at least one of Rto Ris deuterium.89. A composition comprising at least one compound according to and at least one other component.90. The composition of claim 89 , which is formulated for transdermal delivery.91. The composition of claim 90 , which is formulated for transdermal delivery with a patch.92. The composition of claim 89 , further comprising at least one solvent.93. A method of treating pulmonary hypertension claim 82 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt claim 82 , solvate claim 82 , polymorph or enantiomer thereof.94. The method of claim 93 , wherein the pulmonary hypertension is pulmonary arterial hypertension.95. The method of claim 93 , wherein the compound is administered topically.96. The method of claim 95 , wherein the compound is administered transdermally.97. The method of claim 96 , wherein the compound is administered via a transdermal patch.98. The method of claim 93 , further comprising administering an additional therapeutic agent.99. The method of claim 98 , wherein the additional therapeutic agent is selected from the group consisting of vasoactive agents claim 98 , diuretics claim 98 , anticoagulants and cardiac glycosides. This application is a ...

Подробнее
Номер записи: 29
25-03-2021 дата публикации

DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES

Номер: US20210085580A1
Автор: Jia Qi, Zhao Ji-Fu
Принадлежит: Unigen, Inc.

The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier. 140-. (canceled)42. The method of claim 41 , wherein the compound is selected from the group consisting of 1-(2 claim 41 ,4-dihydroxyphenyl)-3-(3′ claim 41 ,4′-dihydroxyphenyl)-1-propanol claim 41 , 1-(2 claim 41 ,4-dihydroxyphenyl)-3-(3′ claim 41 ,4′-dimethoxyphenyl)-1-propanol claim 41 , 1-(2 claim 41 ,4-dihydroxyphenyl)-3-(2′-hydroxyphenyl)-1-propanol claim 41 , 1-(2 claim 41 ,4-dihydroxyphenyl)-3-(2′-methoxyphenyl)-1-propanol claim 41 , 1-(2 claim 41 ,4-dihydroxyphenyl)-3-(4′-methoxyphenyl)-1-propanol claim 41 , 1-(2 claim 41 ,4 claim 41 ,6-trihydroxyphenyl)-3-(4′-aminophenyl)-1-propanol claim 41 , dihydroxyphenyl)-3-phenyl-1-propanol claim 41 , 1-(2 claim 41 ,4-dihydroxyphenyl)-3-(3′- ...

Подробнее
Номер записи: 30
24-03-2016 дата публикации

Compound and Electrolyte of Lithium Secondary Battery Containing the Same

Номер: US20160087309A1
Автор: KIM Cheol Woo, Kim Jin Sung, LEE Kwang Kuk, Lee Seong Il, Oh Seung Yon
Принадлежит:

Provided are a novel compound, an electrolyte for a lithium secondary battery containing the same, and a lithium secondary battery containing the electrolyte for a lithium secondary battery according to the present invention. The electrolyte for a secondary battery according to the present invention may have significantly excellent high-temperature stability, low-temperature discharge capacity, and life cycle characteristics. 3. The compound of claim 2 , wherein Rto Rare each independently hydrogen claim 2 , cyano claim 2 , halo(C1-C10)alkyl claim 2 , or (C1-C10)alkoxycarbonyl.7. The electrolyte for a secondary battery of claim 4 , wherein the compound represented by Chemical Formula 1 is contained at a content of 0.1 to 5 wt % based on a total weight of the electrolyte.8. The electrolyte for a secondary battery of claim 4 , further comprising one or two or more additives selected from the group consisting of oxalatoborate based compounds claim 4 , carbonate based compounds substituted with fluorine claim 4 , vinylidene carbonate based compounds claim 4 , and compounds containing a sulfinyl group.9. The electrolyte for a secondary battery of claim 8 , further comprising an additive selected from the group consisting of lithium difluoro(oxalato)borate (LiFOB) claim 8 , lithium bis(oxalato)borate (LiB(CO) claim 8 , LiBOB) claim 8 , fluoroethylene carbonate (FEC) claim 8 , vinylene carbonate (VC) claim 8 , vinylethylene carbonate (VEC) claim 8 , divinyl sulfone claim 8 , ethylene sulfite claim 8 , propylene sulfite claim 8 , diallyl sulfonate claim 8 , ethane sultone claim 8 , propane sultone (PS) claim 8 , butane sultone claim 8 , ethene sultone claim 8 , butene sultone claim 8 , and propene sultone (PRS).10. The electrolyte for a secondary battery of claim 8 , wherein the additive is contained at a content of 0.1 to 5.0 wt % based on a total weight of the electrolyte.11. The electrolyte for a secondary battery of claim 4 , wherein the non-aqueous organic solvent is ...

Подробнее
Номер записи: 31
29-03-2018 дата публикации

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Номер: US20180086730A1
Автор: BECKER Cyrus K., Pfister Jürg, Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит:

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 147-. (canceled)49. The compound of claim 48 , wherein R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , and Rare H.50. The compound of claim 48 , wherein at least one of R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , R claim 48 , and Rare is deuterium.51. The compound of claim 48 , wherein Lis —O-alkylene-C(O)—.52. The compound of claim 48 , wherein Lis —O-alkylene-OC(O)—.53. The compound of claim 48 , wherein Lis a bond.54. The compound of claim 48 , wherein the alkylene group is a C-Calkylene group.55. The compound of claim 48 , wherein the alkylene group is a Calkylene group.56. (canceled)5863-. (canceled)66. A composition comprising a compound of claim 48 , or and one or more pharmaceutically acceptable excipients.67. The composition of claim 66 , which is formulated for transdermal delivery.6870-. (canceled)71. A method of treating pulmonary hypertension claim 66 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of claim 66 , or or a pharmaceutically acceptable salt thereof.72. The method of claim 71 , wherein the pulmonary hypertension is pulmonary arterial hypertension.73. The method of claim 71 , wherein the compound is administered transdermally. This application claims priority to U.S. provisional application 61/751,608 filed Jan. 11, 2013 ...

Подробнее
Номер записи: 32
21-03-2019 дата публикации

CHEMICAL TOOLS FOR IMAGING PHOSPHOLIPASE D ACTIVITY

Номер: US20190085373A1
Автор: BASKIN Jeremy, BUMPUS Timothy, LIANG Dongjun
Принадлежит:

A method for detecting phospholipase D (PLD) activity in a cell, comprising: (i) stimulating endogenous PLD in said cell for said PLD to catalyze a transphosphatidylation reaction between phosphatidylcholine or a derivative thereof and an exogenous functionalized alcohol to form a phosphatidyl alcohol, wherein the functionalized alcohol possesses a first functional group that can react with and form a bond to a functionalized detectable label having a second functional group reactive with the first functional group, and said phosphatidyl alcohol contains said first functional group in available form; (ii) reacting said phosphatidyl alcohol with said functionalized detectable label under conditions where said functionalized detectable label reacts, via its second functional group, with the first functional group to form a linkage between said detectable label and said phosphatidyl alcohol so as to form a labeled phosphatidyl alcohol containing said detectable label; and (iii) detecting said labeled phosphatidyl alcohol. 1. A method for detecting phospholipase D (PLD) activity in a cell , the method comprising:(i) stimulating endogenous PLD in said cell while said cell is in contact with an exogenous functionalized alcohol containing at least one carbon atom in order for said PLD to catalyze a transphosphatidylation reaction between phosphatidylcholine or a derivative thereof and said exogenous functionalized alcohol to form a phosphatidyl alcohol, wherein said exogenous functionalized alcohol possesses a first functional group that can react with and form a bond to a functionalized detectable label having a second functional group reactive with the first functional group, and said phosphatidyl alcohol contains said first functional group in available form, as provided by the exogenous functionalized alcohol;(ii) reacting said phosphatidyl alcohol with said functionalized detectable label under conditions where said functionalized detectable label reacts, via its ...

Подробнее
Номер записи: 33
30-03-2017 дата публикации

MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME

Номер: US20170088536A1
Автор: Foley Patrick, YANG Yonghua
Принадлежит:

The application relates to macrocyclic compounds and related polymers, as well as to processes for synthesizing them, e.g., using olefins as starting material. 24.-. (canceled)5. The compound of claim 1 , wherein claim 1 , for the compound of Formula I claim 1 , the number of atoms comprising the ring structure is between 13 and 19.6. The compound of claim 1 , wherein X is O.7. The compound of claim 1 , wherein X is NH.8. The compound of claim 1 , wherein Z is hydrogen.10. The compound of claim 1 , wherein Ris optionally substituted linear CCalkyl branched C-Calkyl claim 1 , unsubstituted linear C-Calkyl claim 1 , optionally substituted linear C-Calkenyl claim 1 , unsubstituted linear C-Calkenyl or branched C-Calkenyl.1113.-. (canceled)14. The compound of claim 1 , wherein Ris optionally substituted linear CCalkyl claim 1 , unsubstituted linear CCalkyl or branched C-Calkyl.15. The compound of claim 1 , wherein Ris linear CCalkyl or branched C-Calkyl substituted with one or more hydroxyl groups.16. (canceled)17. The compound of claim 1 , wherein Ris optionally substituted linear C-Calkenyl claim 1 , unsubstituted linear C-Calkenyl or branched C-Calkenyl.18. (canceled)19. The compound of claim 1 , wherein Ris optionally substituted linear C-Calkynyl claim 1 , unsubstituted linear C-Calkynyl or branched C-Calkynyl.20. (canceled)24. (canceled)25. The method of claim 23 , further comprising an amidation step claim 23 , wherein a compound of Formula I claim 23 , wherein X is O claim 23 , reacts with NHunder an elevated pressure to obtain a corresponding compound of Formula I claim 23 , wherein X is NH.26. (canceled)27. The method of claim 23 , wherein the esterification step is performed at a first temperature that is greater than room temperature claim 23 , and the etherification step is performed at a second temperature that is lower than the first temperature.2833.-. (canceled)34. The method of claim 23 , wherein the etherification step is quenched with a base.35. ( ...

Подробнее
Номер записи: 34
02-04-2015 дата публикации

MACROCYCLIC PICOLINAMIDE COMPOUNDS WITH FUNGICIDAL ACTIVITY

Номер: US20150094339A1
Автор: "OCallaghan Ian", DeLorbe Johnathan E., Dent, III William, Martin Timothy P., Meyer Kevin G., Nugent Benjamin, Owen W. John, Wilmot Jeremy, Wilson Anne M., Yao Chenglin
Принадлежит:

The invention relates to compounds of macrocyclic picolinamides of Formula I suitable to control or prevent growth of fungi. 2. The compound according to claim 1 , wherein X and Y are independently chosen from H or C(O)R.3. The compound according to claim 2 , wherein Ris chosen from H claim 2 , alkyl claim 2 , alkenyl claim 2 , aryl claim 2 , —Si(R) claim 2 , or —C(O)R claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 3 , wherein Ris chosen from H claim 3 , alkyl claim 3 , aryl claim 3 , heteroaryl claim 3 , or arylalkyl claim 3 , each optionally substituted with 0 claim 3 , 1 or multiple R.5. The compound according to claim 1 , wherein X is H and Y is Q.6. The compound according to claim 5 , wherein Ris chosen from H claim 5 , alkyl claim 5 , alkenyl claim 5 , aryl claim 5 , —Si(R) claim 5 , or —C(O)R claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.7. The compound according to claim 6 , wherein Ris chosen from H claim 6 , alkyl claim 6 , aryl claim 6 , heteroaryl claim 6 , or arylalkyl claim 6 , each optionally substituted with 0 claim 6 , 1 or multiple R.8. The compound according to claim 7 , wherein Ris H claim 7 , —C(O)R claim 7 , or —CHOC(O)R.9. The compound according to claim 8 , wherein Ris alkyl or alkoxy claim 8 , each optionally substituted with 0 claim 8 , 1 claim 8 , or multiple R.10. A formulation for the control of a fungal pathogen claim 8 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'at least one of the compounds of ; and'}a phytologically acceptable carrier material.11. The formulation according to claim 10 , wherein the formulation is suitable for treating plants.12. A formulation for the control of a fungal pathogen claim 10 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'at least one of the compounds of ; and'}at least one agriculturally active ingredient selected from the group consisting of: fungicides, insecticides, nematocides, ...

Подробнее
Номер записи: 35
02-04-2015 дата публикации

Use of macrocyclic picolinamides as fungicides

Номер: US20150094340A1
Автор: Anne M. WILSON, Benjamin Nugent, Chenglin Yao, Ian O'CALLAGHAN, Jeremy Wilmot, Johnathan E. DELORBE, Kevin G. Meyer, Timothy P. Martin, W. John OWEN, William Dent, Iii
Принадлежит: DOW AGROSCIENCES LLC

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.

Подробнее
Номер записи: 36
12-05-2022 дата публикации

CHRYSOPHAENTIN ANALOGS AND USE THEREOF

Номер: US20220144794A1
Автор: Fullenkamp Christopher, Jana Somnath, KIM Kwangho, Sulikowski Gary A.
Принадлежит:

Provided are 9-dechlorochrysophaentin analog compounds and the synthesis process thereof. The disclosed compound have remarkable antimicrobial activities that are comparable to, or even more potent than, the natural product chrysophaentin A. Also provided are method of inhibiting bacterial growth or treating bacterial infection by administering an effective amount of the disclosed compounds. 3. The compound of any one of - , or a pharmaceutically acceptable salt thereof , wherein Y is halogen and Z is H.4. The compound of any one of - , or a pharmaceutically acceptable salt thereof , wherein Y is H and Z is halogen.5. The compound of any one of - , or a pharmaceutically acceptable salt thereof , wherein R , R , R , R , R , and Rare independently H or Calkyl.6. The compound of any one of - , or a pharmaceutically acceptable salt thereof , wherein R , R , R , R , R , and Rare independently H , methyl , or isopropyl.7. The compound of any one of - , or a pharmaceutically acceptable salt thereof , wherein R , R , and Rare H; and R , R , and Rare independently H , methyl , or isopropyl.8. The compound of any one of - , or a pharmaceutically acceptable salt thereof , wherein R , R , Rand Rare H; and Rand Rare independently H , methyl , or isopropyl.9. The compound of any one of - , or a pharmaceutically acceptable salt thereof , wherein{'sup': 1', '2', '3', '4', '5', '6, 'R, R, RR, R, and Rare H, Y is halogen, Z is H;'}{'sup': 1', '2', '3', '4', '5', '6, 'R, R, RR, R, and Rare H, Y is H, Z is halogen;'}{'sup': 1', '2', '3', '4', '5', '6, 'R, R, Rand Rare H; Rand Rare methyl, Y is halogen, Z is H; or'}{'sup': 1', '2', '3', '4', '5', '6, 'R, R, Rand Rare H; Rand Rare methyl, Y is H, Z is halogen.'}10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof claim 9 , wherein{'sup': 1', '2', '3', '4', '5', '6, 'R, R, RR, R, and Rare H, Y is Cl, and Z is H.'}11. The compound of claim 9 , or a pharmaceutically acceptable salt thereof claim 9 , wherein{'sup': 1', ...

Подробнее
Номер записи: 37
28-03-2019 дата публикации

FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION

Номер: US20190092720A1
Автор: BLOCK Timothy M., Du Yanming, Guo Ju-Tao, Xu Xiaodong
Принадлежит:

Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection. 2. The compound of claim 1 , wherein X is CH and n is 1.3. The compound of claim 1 , wherein X is S and n is 0.4. The compound of claim 1 , wherein m is 0.5. The compound of claim 1 , which is selected from the group consisting of:3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3,4-difluoro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide;or a hydrate, solvate, or salt thereof.6. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and at least one compound of .7. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and at least one compound selected from the group consisting of:3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3,4-difluoro-phenyl)-amide;3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (3-chloro-4-fluoro-phenyl)-amide;or a hydrate, solvate, or salt thereof.8. A method for treating or ameliorating a disease or disorder that involves pregenomic RNA encapsidation claim 1 , the method comprising administering to a subject a therapeutically effective amount of at least one compound of .9. The method of claim 8 , wherein the disease or disorder is hepatitis B.10. The method of claim 8 , wherein the at least one compound is administered as part of a pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.11. A method of treating or ameliorating hepatitis B in a subject infected with hepatitis B virus claim 1 , the method comprising administering to the subject a therapeutically amount of at least one ...

Подробнее
Номер записи: 38
03-07-2014 дата публикации

SYNTHESIS AND USE OF ISOTOPICALLY LABELED MACROCYCLIC COMPOUNDS

Номер: US20140186873A1
Автор: Johnson Peter Lee, JR. Ronald, Meyer Kevin G., Ross
Принадлежит:

Disclosed herein are isotopically labeled antifungal antibiotics and related compounds. Also disclosed are methods for synthesizing these isotopically labeled molecules and using the same to study the distribution of these compounds in the biosphere as well as the products formed by the breakdown of these isotopically labeled compounds. 4. The compound according to claim 1 , wherein Ris H.9. The compound according to claim 5 , wherein Ris Ph-C10. The compound according to claim 5 , wherein Ris Ph-UL-C.12. The method according to claim 11 , wherein the compound is (a) and the sample is a portion of a plant.13. The method according to claim 11 , wherein the compound is (a) and the sample is from a surface adjacent to a plant.14. The method according to claim 11 , wherein the compound is (a) and the sample is from a material that is in communication with a surface adjacent to a plant.15. The method according to claim 11 , where the compound is (a) and the isotopically labeled signature is contained in a portion of said compound.16. The method according to claim 11 , wherein the compound is (b) and the sample is a portion of a plant.17. The method according to claim 11 , wherein the compound is (b) and the sample is from a surface adjacent to a plant.18. The method according to claim 11 , wherein the compound is (b) and the sample is from a material that is in communication with a surface adjacent to a plant.19. The method according to claim 11 , where the compound is (b) and the isotopically labeled signature is contained in a portion of said compound. This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/747,699 filed Dec. 31, 2012, which is expressly incorporated by reference herein.Aspects of the invention include the preparation and use of isotopically labeled compounds including radiolabeled forms of the antifungal antibiotic UK-2A and related compounds.Isotopically labeled compounds are important tools in characterizing the role ...

Подробнее
Номер записи: 39
03-07-2014 дата публикации

Dioxirane compounds and uses thereof

Номер: US20140187467A1
Автор: Kraig Anderson
Принадлежит: Individual

A dioxirane-containing compound has a first substituent that is an alkyl, polyalkoxy, aryl, heteroaryl, or heterocyclyl group, and a second substituent that is an electron withdrawing group, and where the first and second substituents can optionally join to form a cycloalkyl or heterocyclyl group. The dioxirane-containing compound can be used as an oxidant, surfactant, and/or an ionic liquid.

Подробнее
Номер записи: 40
29-04-2021 дата публикации

Amphiphilic and Mesogenic Organic Dyes for Tailor-Made Reflective Low-Dimensional Materials

Номер: US20210122742A1
Автор: Dupeyre Grégory, Laine Philippe, Marvaud Valerie, Poulard Laurélie
Принадлежит:

The present invention relates to a compound of the following formula (I): 2. The compound according to claim 1 , wherein R═R′.5. The compound according to any one of to claim 1 , wherein Rrepresents a halogen atom claim 1 , a (C-C)alkyl claim 1 , (C-C)haloalkyl claim 1 , (CH)OR claim 1 , (CH)SR claim 1 , OR claim 1 , SRor NRRgroup claim 1 , wherein m and m′ are claim 1 , independently of each other claim 1 , equal to 1 claim 1 , 2 or 3 claim 1 , preferably 1.6. The compound according to any one of to claim 1 , wherein:{'sub': 4', '1', '20', '1', '20', '2', 'm', '24', '2', 'm', '25', '26', '27', '28', '29, 'Rrepresents a halogen atom, a (C-C)alkyl, (C-C)haloalkyl, (CH)OR, (CH)SR, OR, SRor NRRgroup wherein m and m′ are, independently of each other, equal to 1, 2 or 3, preferably 1;'}or{'sub': 4', '42', '43', '2', 'n', '44', '45', '2', '2, 'claim-text': Y and Y′ each represent, independently of each other, O, S or NH,', 'n is equal to 2 or 3,', {'sub': 42', '43', '1', '6, 'Rand R, each represent, independently of each other, a (C-C)alkyl group, and'}, {'sub': 44', '45', '1', '6, 'Rand Reach represent, independently of each other, a (C-C)alkyl group.'}], 'both Rgroups form together a bond or a chain selected from the group consisting of —C(RR)—, —(CH)—, —Si(RR)— and —Y—CH—CH—Y′—, wherein7. The compound according to any one of to claim 1 , wherein L represents a bond.8. The compound according to any one of to claim 1 , wherein Rand Reach represent claim 1 , independently of each other claim 1 , a hydrogen atom claim 1 , a halogen atom claim 1 , a (C-C)alkyl or (C-C)haloalkyl group claim 1 , notably a hydrogen atom or a (C-C)alkyl group claim 1 , preferably Rand Rboth represent a hydrogen atom.9. The compound according to any one of to claim 1 , wherein R═Rand/or R═Rand/or R═R.11. The compound according to any one of to claim 1 , wherein A represents a hexafluorophosphate claim 1 , tetrafluoroborate claim 1 , tetraphenylborate claim 1 , 2 claim 1 ,3-dichloro-5 claim 1 ,6- ...

Подробнее
Номер записи: 41
03-05-2018 дата публикации

BROMINE-SENSITIZED SOLAR PHOTOLYSIS OF CARBON DIOXIDE

Номер: US20180119275A1
Автор: BRAIMAN Mark S.
Принадлежит:

There is described a process for depositing carbon on a surface, comprising, while contacting a mixture of COand Brwith a polar substrate presenting apposed surfaces, exposing a sufficient area of said mixture in the region of said apposed surfaces to light of sufficient intensity and frequency to result in deposition of carbon on at least some of said apposed surfaces. Other embodiments are also described. 146-. (canceled)47. A composition of matter comprising a chemical compound of the formula COBr.48. The composition of matter of claim 47 , wherein said chemical compound of formula COBris a substituted 1 claim 47 ,3-dioxetane.49. The composition of matter of claim 48 , where the substituted 1 claim 48 ,3-dioxetane is 2 claim 48 ,4-dibromo-2 claim 48 ,4-dihypobromo-1 claim 48 ,3-dioxetane.50. The composition of matter of claim 49 , where the 2 claim 49 ,4-dibromo-2 claim 49 ,4-dihypobromo-1 claim 49 ,3-dioxetane has the two hypobromo groups in a trans configuration.51. The composition of matter of claim 49 , where the 2 claim 49 ,4-dibromo-2 claim 49 ,4-dihypobromo-1 claim 49 ,3-dioxetane has the two hypobromo groups in a cis configuration.52. The composition of matter according to claim 47 , wherein the composition of matter consists essentially of said compound.53. The composition of matter according to claim 48 , wherein the composition of matter consists essentially of said compound.54. The composition of matter according to claim 49 , wherein the composition of matter consists essentially of said compound.55. The composition of matter according to claim 50 , wherein the composition of matter consists essentially of said compound.56. The composition of matter according to claim 51 , wherein the composition of matter consists essentially of said compound.57. A chemical compound of the formula COBr.58. The chemical compound of claim 57 , wherein said chemical compound is a substituted 1 claim 57 ,3-dioxetane.59. The chemical compound of claim 58 , where the ...

Подробнее
Номер записи: 42
25-04-2019 дата публикации

TERTIARY AMIDES AND METHOD OF USE

Номер: US20190119200A1
Автор: Black Lawrence A., Bunnelle William H., Chen Da, Clapham Bruce, DeGoey David A., DENG Xiangjun, Fu Liqiang, Hazelwood Lisa A., KONG Linglong, Lang Qingyu, Lee Chih-Hung, Li Mingfeng, Lundgaard Greta L., Patel Meena V., Tao Ruihong, Zhang Lin, Zhang Qingwei, ZHENG Qiangang, Zhu Wei
Принадлежит:

Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G, G, G, L, L, and Lare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions. 5. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '2', 'sub': 1', '3', '1', '3', '1', '3', '1', '3, 'Gis phenyl; wherein the phenyl is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from C-Calkoxy, C-Calkyl, or halogen, wherein the C-Calkyl and C-Calkoxy are unsubstituted or optionally substituted with one, two, or three fluorines.'}6. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '2', 'sub': 1', '3', '1', '3, 'Gis selected from the group consisting of 2-furanyl and 2-thiophenyl; wherein the 2-furanyl and 2-thiophenyl are unsubstituted or optionally substituted with 1 or 2 substituents independently selected from halogen or C-Calkyl, wherein the C-Calkyl is unsubstituted or optionally substituted with one, two, or three fluorines.'}7. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '3', 'sub': '2', 'Gis —COH.'}8. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '3', 'sub': 2', '1', '6', '3, 'Gis selected from the group consisting of —P(O)(OH), —P(O)(OH)(OC-Calkyl), and —P(O)(CH)(OH).'}9. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '3', 'sub': 2', '3', '3, 'Gis selected from the group consisting of —B(OH), —SOH, —CH(OH)CF, —C(O)NH(OH), and —C(O)NH(CN).'}10. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': 3', 'G3a', 'G3a', 'G3a', 'G3a', 'G3a', 'G3a', ' ...

Подробнее
Номер записи: 43
25-04-2019 дата публикации

COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS

Номер: US20190119311A1
Автор: Frater Georg, Ondi Levente, TOTH Florian
Принадлежит:

The disclosure provides Group 6 complexes, which, in some embodiments, are useful for catalyzing olefin metathesis reactions. In some embodiments, the compounds are compounds of the following formula: 2. The compound of claim 1 , wherein Ris phenyl claim 1 , 2 claim 1 ,6-dichlorophenyl claim 1 , 2 claim 1 ,6-dimethylphenyl claim 1 , 2 claim 1 ,6-diisopropylphenyl claim 1 , 2-trifluoromethylphenyl claim 1 , pentafluorophenyl claim 1 , tert-butyl claim 1 , or 1-adamantyl.3. The compound of claim 1 , wherein Ris pyrrol-1-yl claim 1 , 2 claim 1 ,5-dimethylpyrrol-1-yl claim 1 , 2 claim 1 ,5-diphenylpyrrol-1-yl claim 1 , or indol-1-yl.5. The compound of claim 1 , wherein Ris methyloxy claim 1 , ethyloxy claim 1 , or isopropyloxy.6. The compound of claim 1 , wherein Rand Rare independently a hydrogen atom claim 1 , methyl claim 1 , a halogen atom claim 1 , or methyloxy.7. A method for carrying out a metathesis reaction claim 1 , the method comprising:providing a first compound having one or more carbon-carbon double bonds; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting the first compound via a metathesis reaction in the presence of a compound of .'}8. The method of claim 7 , wherein the first compound has two or more carbon-carbon double bonds.9. The method of claim 8 , wherein the metathesis reaction is a ring-closing metathesis reaction between two of the two or more carbon-carbon double bonds of the first compound.10. A method of carrying out a metathesis reaction claim 8 , the method comprising:providing a first compound having one or more carbon-carbon double bond and a second compound having one or more carbon-carbon double bonds; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'reacting the first compound and the second compound via a metathesis reaction in the presence of a compound of .'}11. The method of claim 10 , wherein the first compound and the second compound are the same compound.12. The method of claim 10 , wherein the first compound ...

Подробнее
Номер записи: 44
16-04-2020 дата публикации

NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT

Номер: US20200115359A1
Автор: SØLVHØJ Amanda Birgitte, TAARNING Esben
Принадлежит: Haldor Topsoe A/S

New adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and a co-monomer useful for the preparation of polymers and co-polymers. Also, a process of preparing the new adipate-type compounds from bio-based raw materials such as sugars. 2. The compound according to claim 1 , wherein n is 2.3. The compound according to claim 1 , wherein n is 3.5. The process according to claim 4 , wherein n is 2.6. The process according to claim 4 , wherein n is 3.7. The process according to claim 4 , wherein the conversion temperature of iii) is in the range of from 20 to 120° C.8. The process according to claim 4 , wherein step iii) is continued for a period of time in the range of from 5 minutes to 24 hours.9. The process according to claim 4 , wherein the conversion step of iii) is conducted at a pressure in the range of from 1 to 1000 kPa claim 4 , such as from 10 to 125 kPa.10. The process according to claim 4 , wherein the conversion step of iii) is conducted in the presence of a solvent selected from methyl lactate claim 4 , ethyl lactate claim 4 , toluene claim 4 , dichlormethane claim 4 , or mixtures thereof. The present application is a divisional of U.S. application Ser. No. 16/096,103, filed on Oct. 24, 2018, which is a U.S. National Stage of International Application No. PCT/EP2017/060702, filed on May 4, 2017, which claims the benefit of Danish Application No. PA 2016-00273, filed on May 4, 2016. The entire contents of each of U.S. application Ser. No. 16/096,103, International Application No. PCT/EP2017/060702, Danish Application No. PA 2016-00273 are hereby incorporated herein by reference in their entirety.The present invention regards a new compound suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and co-polymers. The invention also regards the ...

Подробнее
Номер записи: 45
16-04-2020 дата публикации

ENZYME-TRIGGERED CARBON MONOXIDE RELEASING MOLECULES

Номер: US20200115360A1
Автор: Ji Xingyue, Wang Binghe
Принадлежит:

The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs. The compounds disclosed herein contain a cyclopentadienone moiety, a non-reactive dienophile, and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile. Cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile 1. A compound comprising a cyclopentadienone moiety , a non-reactive dienophile , and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile , wherein cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile.3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein the moiety —X—Y— is —O—C(O)—.4. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein Rand Rare taken together to form a fused tricyclic moiety.7. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein{'sup': 1a', '1b', '1c, 'Ris selected from the group consisting of 3- to 8-membered heterocyclyl and —NRR,'}{'sup': '1b', 'sub': '1-8', 'Ris selected from H and Calkyl; and'}{'sup': '1c', 'sub': '1-8', 'Ris selected from H, Calkyl, and a solubilizing moiety.'}8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein the solubilizing moiety is selected from the group consisting of an oligo(ethylene glycol) claim 7 , a poly(ethylene glycol) claim 7 , and a monosaccharide.10. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable excipient.11. A method for delivering carbon monoxide to a subject in need thereof claim 1 , the method comprising administering to the subject a compound according to .12. A method for treating a disease or condition ...

Подробнее
Номер записи: 46
07-08-2014 дата публикации

Compounds that Modulate Store Operated Calcium Channels

Номер: US20140221468A1
Автор: Dolmetsch Ricardo Ei, PARK Chan Young, Sadaghiani Amir M.
Принадлежит: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Store operated calcium channel modulating compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which modulation of store operated calcium channels is desired. 1. A method for modulating a store operated calcium channel in a cell , the method comprising:contacting the cell with a store operated calcium channel modulating effective amount of a compound selected from the group consisting of a chromenone, an octahydro-naphthalene, a dibenzo-diheteropin-1 1-one, a 3a,7a-dihydro-4H-benzofuran-5-one, a tetrahydro-furo[3,4-c]furan-1-one and a 3,3a,4,5-tetrahydro-2H-benzofuran-6-one.22. A pharmaceutical composition comprising a store operated calcium channel modulating compound selected from the group consisting of a chromenone , an octahydro-naphthalene , a dibenzo-diheteropin-11-one , a dihydro-benzofuran-5-one , a tetrahydro-furofuran-1-one and a tetrahydro-benzofuran-6-one. This invention was made with Government support under grants R01 NS048564 and R01 GM45374 awarded by the National Institutes of Health. The Government has certain rights in this invention.Calcium has an important role in many cellular functions such as the transduction of signals into and within cells. Processes that depend on calcium are involved in cellular responses to growth factors, neurotransmitters, hormones and other signal molecules. Intracellular calcium concentrations are tightly controlled by a variety of pumps and channels. As calcium is the most abundant second messenger in cell signaling, such tight control is necessary to produce specific calcium mediated responses.Store Operated Calcium Entry, which involves Calcium Release-Activated Calcium (CRAC) channels and their currents (I), is one of many ways of regulating intracellular calcium levels. Store-operated calcium channels (SOCs) comprise the major receptor-activated calcium entry pathway in non-excitable mammalian cells and play important roles in the control ...

Подробнее
Номер записи: 47
08-09-2022 дата публикации

NOVEL LOBARIC ACID DERIVATIVE HAVING PTP-1B INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF

Номер: US20220281805A1
Автор: Han Se Jong, HONG Ju Mi, JO Dong Gyu, Kang Pil Sung, Kim Il Chan, KIM Jung Eun, Kim Kyung Hee, Kim Min Ju, Kim Sung Jin, Kim Tai Kyoung, MIN Seul Ki, OH Hyun Cheol, Park Ha Ju, Yim Joung Han
Принадлежит:

A lobamide compound according to an embodiment of the present disclosure is represented by Formula 1. The lobamide compound has excellent PTP-1B inhibitory activity that is far higher than that of conventional lobaric acid derivatives and which can be orally administered, and thus is very effective in the prevention or treatment of diabetes or obesity through oral administration. 5Stereocaulon alpinum.: The method according to claim 4 , wherein the lobaric acid is extracted from6: The method according to claim 4 , further comprising:{'i': 'Stereocaulon alpinum', 'obtaining crystals containing lobaric acid by recrystallizing the extract before performing the (a),'}wherein the (a) comprises:dissolving the crystals in a solvent, adding dimethylamine thereto and stirring the mixture; andafter the stirring, adding an acidic solution thereto to terminate the reaction.7: A method for treatment of diabetes claim 1 , the method comprising administering to a subject in need thereof a composition comprising the lobamide compound according to or a salt thereof as an active ingredient.9: The method according to claim 7 , further comprising an antidiabetic compound.10: The method according to claim 9 , wherein the antidiabetic compound is any one selected from the group consisting of nateglinide claim 9 , repaglinide claim 9 , glitazones claim 9 , sulfonyl urea claim 9 , metformin claim 9 , glimepride claim 9 , thiazolidinedione claim 9 , biguanide claim 9 , acarbose as alpha-glucosidase inhibitor claim 9 , and meglitinide-based frandins.11: The method according to claim 7 , wherein the composition is a health functional food.13: The method according to claim 7 , wherein the composition is a pharmaceutical composition.14Stereocaulon alpinum.: The method according to claim 3 , wherein the compound having the depsidone structure is extracted from15: The method according to claim 3 , further comprising:{'i': 'Stereocaulon alpinum', 'obtaining crystals containing compound having the ...

Подробнее
Номер записи: 48
02-06-2016 дата публикации

SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN

Номер: US20160154304A1
Автор: ANRYU Yukako, ICHIKAWA Koji, OCHIAI Mitsuyoshi
Принадлежит: Sumitomo Chemical Company, Limited

A salt represented by formula (I): 2. The salt according to claim 1 , wherein Xis *—CO—O—.3. The salt according to claim 1 , wherein Ris an adamantyl group.4. An acid generator claim 1 , which comprises the salt according to .5. A resist composition comprising the salt according to and a resin having an acid-labile group.6. The resist composition according to claim 5 , further comprising a salt which generates an acid weaker in acidity than an acid generated from the acid generator.7. A method for producing a resist pattern comprising steps (1) to (5);{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, '(1) applying the resist composition according to onto a substrate;'}(2) drying the applied composition to form a composition layer;(3) exposing the composition layer;(4) heating the exposed composition layer; and(5) developing the heated composition layer. This application claims priority to Japanese Application No. 2014-241765 filed on Nov. 28, 2014. The entire disclosures of Japanese Application No. 2014-241765 is incorporated hereinto by reference.1. Field of the InventionThe disclosure relates to a salt, an acid generator, a resist composition and a method for producing resist pattern.2. Related ArtA resist composition which contains an acid generator including a salt represented by the following formula is described in Patent document of JP 2008-069146A.The present disclosure provides following inventions of <1> to <7>.<1> A salt represented by formula (I):wherein Qand Qeach independently represent a fluorine atom or a Cto Cperfluoroalkyl group,Rand Reach independently represent a hydrogen atom, a fluorine atom or a Cto Cperfluoroalkyl group,z represents an integer of 0 to 6,Xrepresents *—O—, *—CO—O— or *—O—CO—,* represents a binding site to CRRor CQQ,Lrepresents a Cto Calkanediyl group,Rrepresents a Cto Calicyclic hydrocarbon group in which a hydrogen atom may be replaced by a hydroxy group, and in which a methylene group may be replaced by an oxygen atom or a ...

Подробнее
Номер записи: 49
16-05-2019 дата публикации

NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT

Номер: US20190144415A1
Автор: SØLVHØJ Amanda Birgitte, TAARNING Esben
Принадлежит: Haldor Topsoe A/S

The present invention regards new adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and copolymers. The invention also regards the process of preparing the new adipate-type compounds from bio-based raw materials such as sugars.

Подробнее
Номер записи: 50
14-05-2020 дата публикации

Acly inhibitors and uses thereof

Номер: US20200148634A1
Автор: Eric Therrien, Silvana Marcel LEIT DE MORADEI
Принадлежит: Nimbus Artemis Inc

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

Подробнее
Номер записи: 51
18-06-2015 дата публикации

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Номер: US20150166503A1
Автор: BECKER Cyrus K., Pfister Jürg R., Rescourio Gwenaella, Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит:

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 2. The compound of claim 1 , wherein Ris Pand Ris H.3. The compound of claim 1 , wherein Ris H and Ris P.4. The compound of claim 1 , wherein Ris Pand Ris P.615-. (canceled)16. The compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare H claim 1 , or wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare deuterium.17. (canceled)18. The compound of claim 1 , wherein Z is —OR claim 1 , —N(R)R claim 1 , or P.19. (canceled)20. The compound of claim 1 , wherein Z is —OH claim 1 , —OR claim 1 , —N(R)R claim 1 , or P.21. (canceled)22. The compound of claim 1 , wherein Z is not —OH and Ris not unsubstituted or substituted benzyl.25. The compound of claim 24 , wherein Z is —OR.26. The compound of claim 24 , wherein Z is —N(R)R.27. The compound of claim 24 , wherein Z is —SR.28. The compound of claim 24 , wherein Z is P.29. The compound of claim 24 , wherein Z is ORand Ris bicycloalkyl claim 24 , alkylcycloalkyl claim 24 , or alkylcycloheteroalkyl.30. The compound of claim 24 , wherein Ris haloalkyl.31. (canceled)32. The compound of claim 24 , wherein Ris hydrogen and Ris P.33. The compound of claim 24 , wherein Ris Pand Ris hydrogen.34. The compound of claim 24 , wherein Ris Pand Ris P.35. The compound of claim 24 , wherein Rand Rare each hydrogen.36. A compound according to claim ...

Подробнее
Номер записи: 52
24-06-2021 дата публикации

Compound, mixture, liquid crystal composition, cured product, optically anisotropic body, and reflective film

Номер: US20210189243A1
Автор: Keisuke KODAMA, Shunya Katoh, Yuko Suzuki
Принадлежит: Fujifilm Corp

An object of the present invention is to provide a compound which increases the intensity of HTP by exposure to irradiation with light such as ultraviolet rays, and a mixture including the compound. Another object of the present invention is to provide a liquid crystal composition, a cured product, an optically anisotropic body, and a reflective film.The compound of the present invention is represented by General Formula (1).

Подробнее
Номер записи: 53
16-06-2016 дата публикации

IRE-1alpha Inhibitors

Номер: US20160168116A1
Автор: Flynn Gary A., Lonergan David G., PALLAI Peter V., Patterson John B., Zeng Qingpeng
Принадлежит:

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. 14. The compound or the pharmaceutically acceptable salt thereof of claim 11 , wherein Ris selected from the group consisting of hydrogen claim 11 , —F claim 11 , —CF claim 11 , —NO claim 11 , and —OCH.20. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The invention relates to IRE-1α inhibitors and their therapeutic uses.Protein folding stress in the endoplasmic reticulum of a cell initiates a signal transduction cascade termed the unfolded protein response or UPR. A key enzyme, inositol requiring enzyme 1 (IRE-1α), relieves protein folding stress by enhancing molecular chaperone activity and therefore protects cells from stress induced apoptosis. Inhibitors of IRE-1α are useful for treating at least B cell autoimmune diseases, certain cancers, and some viral infections.The invention provides IRE-1α inhibitor compounds and prodrugs and pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions and methods of using the IRE-1α inhibitor compounds, prodrugs, and pharmaceutically acceptable salts thereof therapeutically to treat disorders associated with the unfolded protein response. Patients who can be treated include those with B cell autoimmune diseases, certain cancers, and some viral infections.The present invention comprises numerous chemical compounds related by structure and by function, as well as methods for their use. Various groupings of these compounds comprising from one to any number of them, and their uses, can be defined and constitute individual embodiments of the invention. Some embodiments will specifically include certain compounds ...

Подробнее
Номер записи: 54
14-06-2018 дата публикации

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Номер: US20180162829A1
Автор: BECKER Cyrus K., Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит:

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 157-. (canceled)60. The compound of claim 58 , wherein R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , and Rare H.61. The compound of claim 58 , wherein at least one of R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , R claim 58 , and Ris deuterium.62. (canceled)64. (canceled)65. (canceled)66. A composition comprising a compound of or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipients.67. The composition of claim 66 , which is formulated for transdermal delivery.68. The composition of claim 66 , which is formulated for transdermal delivery with a patch.6972-. (canceled)73. A method of treating pulmonary hypertension claim 58 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.74. (canceled)75. (canceled)76. The method of claim 73 , wherein the compound is administered orally claim 73 , topically or parenterally.77. The method of claim 76 , wherein the compound is administered transdermally.78. The method of claim 73 , wherein the pulmonary hypertension is pulmonary arterial hypertension.79. The method of claim 73 , further comprising administering an additional therapeutic agent.80. The method of claim 79 , wherein the additional therapeutic agent is ...

Подробнее
Номер записи: 55
16-06-2016 дата публикации

Salt, acid generator, photoresist composition, and method for producing photoresist pattern

Номер: US20160170298A1
Автор: Koji Ichikawa, Yukako ANRYU
Принадлежит: Sumitomo Chemical Co Ltd

A salt represented by the formula (I): wherein Q 1 and Q 2 each independently represent a fluorine atom or a C 1 to C 6 perfluoroalkyl group; R 1 represents a C 1 to C 12 alkyl group in which a methylene group may be replaced by an oxygen atom or a carbonyl group; A 1 represents a C 2 to C 8 alkanediyl group; and R 2 represents a C 5 to C 18 alicyclic hydrocarbon group in which a hydrogen atom may be replaced by a hydroxy group, and in which a methylene group may be replaced by an oxygen atom or a carbonyl group, and which alicyclic hydrocarbon group may have a cyclic ketal structure optionally having a fluorine atom; and “m” represents an integer of 0, 1, 2 or 3.

Подробнее
Номер записи: 56
25-06-2015 дата публикации

Bimesogenic Compounds and Mesogenic Media

Номер: US20150175883A1
Автор: ADLEM Kevin, NAMUTEBI Mariam, Parri Owain Llyr, Saxton Patricia Eileen, SNOW Benjamin, TUFFIN Rachel
Принадлежит: Merck Patent GmBH

The invention relates to bimesogenic compounds of formula I 4. Bimesogenic compounds according to claim 1 , characterized in that Ris selected from OCF claim 1 , CF claim 1 , F claim 1 , Cl and CN.5. Bimesogenic compounds according to claim 1 , characterized in that Spis —(CH)— and o is 1 claim 1 , 3 or an integer from 5 to 15.6. (canceled)7. Liquid-crystalline medium claim 1 , characterised in that it comprises one or more bimesogenic compounds according to .9. (canceled)10. Liquid crystal device comprising a liquid crystalline medium comprising two or more components claim 1 , one or more of which is a bimesogenic compound of formula I according to .11. Liquid crystal device according to claim 10 , characterized in that it is a flexoelectric device. The invention relates to bimesogenic compounds of formula Iwherein R, R, MG, MGand Sphave the meaning given herein below, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.Liquid Crystal Displays (LCDs) are widely used to display information. LCDs are used for direct view displays, as well as for projection type displays. The electro-optical mode which is employed for most displays still is the twisted nematic (TN)-mode with its various modifications. Besides this mode, the super twisted nematic (STN)-mode and more recently the optically compensated bend (OCB)-mode and the electrically controlled birefringence (ECB)-mode with their various modifications, as e. g. the vertically aligned nematic (VAN), the patterned ITO vertically aligned nematic (PVA)-, the polymer stabilized vertically aligned nematic (PSVA)-mode and the multi domain vertically aligned nematic (MVA)-mode, as well as others, have been increasingly used. All these modes use an electrical field, which is substantially perpendicular to the substrates, respectively to the liquid crystal layer. Besides these ...

Подробнее
Номер записи: 57
01-07-2021 дата публикации

COMPOUND, COMPOSITION, CURED PRODUCT, OPTICALLY ANISOTROPIC BODY, AND REFLECTIVE FILM

Номер: US20210198230A1
Автор: KATOH Shunya, KODAMA Keisuke, Suzuki Yuko
Принадлежит: FUJIFILM Corporation

The present invention provides a compound having an excellent rate of change in HTP due to exposure. The present invention further provides a composition formed of the compound, a cured product, an optically anisotropic body, and a reflective film. 2. The compound according to claim 1 ,{'sup': '1', 'wherein Arepresents an aromatic hydrocarbon ring group or an aromatic heterocyclic group.'}3. The compound according to claim 1 ,{'sup': 1', '2, 'wherein Xand Xare bonded to each other to form a ring.'}4. The compound according to claim 1 ,{'sup': 1', '3', '5, 'wherein at least one of X, X, or Xrepresents the group represented by General Formula (2), and'}{'sup': 2', '4', '6, 'at least one of X, X, or Xrepresents the group represented by General Formula (2).'}5. The compound according to claim 1 ,{'sup': 3', '4', '5', '6, 'wherein at least one of X, X, X, or Xrepresents the group represented by General Formula (2), and'}{'sup': 1', '2, 'claim-text': {'br': None, 'sup': 3', '4', '2, 'sub': 'k', 'R-(A-Z)—*\u2003\u2003(A)'}, 'at least one of Xor Xrepresents a group represented General Formula (A),'}{'sup': 3', '2', '4, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'in General Formula (A), k represents an integer of 2 or more, Rrepresents a hydrogen atom or a substituent, Zrepresents a single bond, —O—, —S—, —CHO—, —CO—, —COO—, —CO—S—, —O—CO—O—, —CO—NH—, —CHS—, —CFO—, —CFS—, —CH═CH—COO—, —CH═CH—OCO—, —OCO—C(CN)═CH—, —COO—CHCH—, —OCO—CHCH—, —COO—CH—, —OCO—CH—, —CH═CH—, —N═N—, —CH═N—N═CH—, —CF═CF—, or —C═C—, Arepresents a hydrocarbon ring group or a heterocyclic group, and * represents a bonding position to the fused ring in General Formula (1).'}6. The compound according to claim 1 , {'br': None, 'sup': 2', '3', '1', '2', 'x, 'sub': 'm', 'R-(A-Z)-ACO—CH═CH—*\u2003\u2003(3)'}, 'wherein the group represented by General Formula (2) is a group represented by General Formula (3),'}{'sup': 2', '1', '2', '3', 'x', '2, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2, ' ...

Подробнее
Номер записи: 58
02-07-2015 дата публикации

USE OF MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20150181868A1
Автор: DeKorver Kyle, DeLorbe Johnathan E., Dent, Heemstra Ronald J., III William H., Meyer Kevin G., Yao Chenglin
Принадлежит:

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A composition according to claim 1 , wherein X is hydrogen and Y is Q.3. A composition according to claim 2 , wherein Ris hydrogen.4. A composition according to claim 3 , wherein Ris chosen from alkyl and aryl claim 3 , each optionally substituted with 0 claim 3 , 1 or multiple R.5. A composition according to claim 3 , wherein Ris chosen from hydrogen claim 3 , alkyl claim 3 , aryl claim 3 , and acyl claim 3 , each optionally substituted with 0 claim 3 , 1 or multiple R.6. A composition according to claim 3 , wherein Ris chosen from alkyl and aryl claim 3 , each optionally substituted with 0 claim 3 , 1 or multiple R claim 3 , and Ris chosen from hydrogen claim 3 , alkyl claim 3 , aryl claim 3 , and acyl claim 3 , each optionally substituted with 0 claim 3 , 1 or multiple R.7. A composition according to claim 2 , wherein Ris —C(O)Ror —CHOC(O)R.8. A composition according to claim 7 , wherein Ris chosen from alkyl and alkoxy claim 7 , each optionally substituted with 0 claim 7 , 1 claim 7 , or multiple R.9. A composition according to claim 8 , wherein Ris chosen from alkyl and aryl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.10. A composition according to claim 8 , wherein Ris chosen from hydrogen claim 8 , alkyl claim 8 , aryl claim 8 , and acyl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.11. A composition according to claim 8 , wherein Ris chosen from alkyl and aryl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R claim 8 , and Ris chosen from hydrogen claim 8 , alkyl claim 8 , aryl claim 8 , and acyl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.12. A composition according to claim 11 , wherein Ris chosen from —CH claim 11 , —CHOCHCH claim 11 , and —CHCHOCH.13. A composition for the control of a fungal pathogen including at least one of the compositions of and a ...

Подробнее
Номер записи: 59
02-07-2015 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20150181869A1
Автор: DeKorver Kyle, DeLorbe Johnathan E., Dent, Heemstra Ronald J., III William H., Meyer Kevin G., Yao Chenglin
Принадлежит:

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A compound according to claim 1 , wherein X and Y are hydrogen.3. A compound according to claim 2 , wherein Ris chosen from alkyl and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.4. A compound according to claim 2 , wherein Ris chosen from hydrogen claim 2 , alkyl claim 2 , aryl claim 2 , and acyl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.5. A compound according to claim 2 , wherein Ris chosen from alkyl and aryl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R claim 2 , and Ris chosen from hydrogen claim 2 , alkyl claim 2 , aryl claim 2 , and acyl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.6. A compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.7. A compound according to claim 6 , wherein Ris chosen from alkyl and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 or multiple R.8. A compound according to claim 6 , wherein Ris chosen from hydrogen claim 6 , alkyl claim 6 , aryl claim 6 , and acyl claim 6 , each optionally substituted with 0 claim 6 , 1 or multiple R.9. A compound according to claim 6 , wherein Ris chosen from alkyl and aryl claim 6 , each optionally substituted with 0 claim 6 , 1 or multiple R claim 6 , and Ris chosen from hydrogen claim 6 , alkyl claim 6 , aryl claim 6 , and acyl claim 6 , each optionally substituted with 0 claim 6 , 1 or multiple R.10. A compound according to claim 1 , wherein X is hydrogen and Y is Q.11. A compound according to claim 10 , wherein Ris hydrogen.12. A compound according to claim 11 , wherein Ris chosen from alkyl and aryl claim 11 , each optionally substituted with 0 claim 11 , 1 or multiple R.13. A compound according to claim 11 , wherein Ris chosen from hydrogen claim 11 , alkyl claim 11 , aryl claim 11 , and acyl claim 11 , each optionally substituted with 0 claim 11 , 1 or multiple ...

Подробнее
Номер записи: 60
22-06-2017 дата публикации

NOVEL ORGANOLEPTIC COMPOUNDS AND THEIR USE IN FLAVOR AND FRAGRANCE COMPOSITIONS

Номер: US20170174650A1
Автор: AGYEMANG David O., Cai Tingwei, CANNON Robert J., Chen Zhen, CURTO Nicole L., JANCZUK Adam Jan, Jones Paul D., KAZIMIERSKI Arkadiusz, LI Jing, Rodriguez David, VAN KIPPERSLUIS BRAIN Anja
Принадлежит:

The present invention is directed to novel organoleptic compounds, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a dental product, an oral hygiene product and a medicinal product comprising the step of incorporating an olfactory acceptable amount of such novel organoleptic compounds, and a process of improving, enhancing or modifying a fragrance composition through the addition of an olfactory acceptable amount of such novel organoleptic compounds. 6. The compound of selected from the group consisting of:3-mercapto-3,7-dimethyl-oct-6-en-1-ol;3-mercapto-3,7-dimethyl-oct-6-enal;S-[1-(2-hydroxy-ethyl)-1,5-dimethyl-hex-4-enyl]-thioacetate; and3-acetylsulfanyl-3,7-dimethyl-oct-6-enyl acetate.7. A flavor composition comprising an olfactory acceptable amount of the compound of any of the preceding claims.8. The flavor composition of further comprising a material selected from the group consisting of a foodstuff claim 7 , a chewing gum claim 7 , a dental product claim 7 , an oral hygiene product and a medicinal product.9. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 1 part per billion to about 1000 parts per million by weight.10. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 10 parts per billion to about 100 parts per million by weight.11. The flavor composition of claim 7 , wherein the olfactory acceptable amount is from about 100 parts per billion to about 10 parts per million by weight.12. A method of improving claim 7 , enhancing or modifying a flavor composition through the addition of an olfactory acceptable amount of the compound of any of the preceding claims.13. A fragrance composition comprising an olfactory acceptable amount of the compound of any of the preceding claims.14. The fragrance composition of further comprising a material selected from the group consisting of a polymer and a non ...

Подробнее
Номер записи: 61
04-06-2020 дата публикации

DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES

Номер: US20200170907A1
Автор: Jia Qi, Zhao Ji-Fu
Принадлежит: Unigen, Inc.

The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier. 133-. (canceled)35. The method of claim 34 , wherein the compound is selected from the group consisting of 1-(2 claim 34 ,4-dihydroxyphenyl)-3-(3′ claim 34 ,4′-dihydroxyphenyl)-1-propanol claim 34 , 1-(2 claim 34 ,4-dihydroxyphenyl)-3-(3′ claim 34 ,4′-dimethoxyphenyl)-1-propanol claim 34 , 1-(2 claim 34 ,4-dihydroxyphenyl)-3-(2′-hydroxyphenyl)-1-propanol claim 34 , 1-(2 claim 34 ,4-dihydroxyphenyl)-3-(2′-methoxyphenyl)-1-propanol claim 34 , 1-(2 claim 34 ,4-dihydroxyphenyl)-3-(4′-methoxyphenyl)-1-propanol claim 34 , 1-(2 claim 34 ,4 claim 34 ,6-trihydroxyphenyl)-3-(4′-aminophenyl)-1-propanol claim 34 , dihydroxyphenyl)-3-phenyl-1-propanol claim 34 , 1-(2 claim 34 ,4-dihydroxyphenyl)-3-(3′- ...

Подробнее
Номер записи: 62
18-09-2014 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20140275171A1
Автор: Boebel Timothy, Bravo-Altamirano Karla, Graupner Paul, Heemstra Ronald J., Herrick Jessica, JR. Kevin G., Li Fangzheng, Meyer, Nugent Benjamin, Owen W. John, Renga James M., Wang Nick X., Yao Chenglin
Принадлежит:

The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A compound according to claim 1 , wherein:{'sub': '6', 'wherein, R is H, or C(O)R;'}{'sub': 1', '6, 'Ris C(O)R;'}{'sub': 2', '5, 'Ris independently or separately H, alkyl, alkenyl, aryl, each substituted with 0, 1 or multiple R;'}{'sub': '3', 'Ris independently or separately H, methyl;'}{'sub': '5', 'Ris alkyl, alkoxy, halo, haloalkyl, or aryl; and'}{'sub': '6', 'Ris alkoxy, or benzyloxy.'}5Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPseudoperonospora cubensisPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 4 , wherein the plant pathogen is least one pathogen selected from the group consisting of: Leaf Blotch of Wheat ( claim 4 , anamorph: ) claim 4 , Wheat Brown Rust () claim 4 , Stripe Rust () claim 4 , Scab of Apple () claim 4 , Blister Smut of Maize () claim 4 , Powdery Mildew of Grapevine () claim 4 , Barley scald () claim 4 , Blast of Rice () claim 4 , Downy Mildew of Cucurbits () claim 4 , Rust of Soybean () claim 4 , Glume Blotch of Wheat () claim 4 , Powdery Mildew of Wheat (f. sp. ) claim 4 , Powdery Mildew of Barley (f. sp. ) claim 4 , Powdery Mildew of Cucurbits () claim 4 , Anthracnose of Cucurbits () claim 4 , Leaf Spot of Beet () claim 4 , Early Blight of Tomato () claim 4 , and Net Blotch of Barley ().6Septoria triticiPuccinia triticinaPhakopsora pachyrhizi. The composition according to claim 5 , wherein the fungal pathogen is at least one of Leaf Blotch of Wheat () claim 5 , Wheat Brown Rust () claim 5 , and Rust of Soybean ().8. The method according to claim 7 , wherein the compound is applied in a mixture with at least one additional compound selected from ...

Подробнее
Номер записи: 63
07-07-2016 дата публикации

Fungicidal Compounds and Methods of Their Use

Номер: US20160192657A1
Автор: Villas-Boas Silas Granato
Принадлежит: AUCKLAND UNISERVICES LIMITED

Antifungal compounds, an antifungal compound extracted from , also known as , methods of producing the antifungal compounds, isolates and compositions comprising the antifungal compounds, and methods of using the antifungal compounds. 120-. (canceled)22. The compound of wherein Ris selected from or is substituted with alkylcarbonylalkyl claim 21 , alkylcarbonyloxyalkyl claim 21 , alkyloxyalkyl claim 21 , alkylsulfonyl claim 21 , alkylsulfinyl claim 21 , alkylthioalkyl claim 21 , hydroxyalkyl claim 21 , mono- or di(alkyl)aminoalkyl claim 21 , or wherein Ris hydrogen claim 21 , hydroxyl claim 21 , or a Cto Calkyl or alkoxy group optionally comprising one or more double bonds claim 21 , and optionally substituted with one or more groups selected from lower alkyl claim 21 , lower alkenyl claim 21 , lower alkoxy claim 21 , hydroxyl and carboxyl claim 21 , or wherein Ris a Cto Calkyl or alkoxy group comprising one or more double bonds claim 21 , and substituted with one or more groups selected from lower alkyl claim 21 , lower alkenyl claim 21 , lower alkoxy claim 21 , hydroxyl and carboxyl.23. The compound of wherein R claim 21 , R claim 21 , R claim 21 , and Rare independently selected from hydrogen claim 21 , alkyl claim 21 , substituted alkyl claim 21 , alkoxy claim 21 , substituted alkoxy claim 21 , halogen claim 21 , methyl claim 21 , methoxy and hydroxyl.24. The compound of wherein R claim 22 , R claim 22 , R claim 22 , and Rare independently selected from hydrogen claim 22 , alkyl claim 22 , substituted alkyl claim 22 , alkoxy claim 22 , substituted alkoxy claim 22 , halogen claim 22 , methyl claim 22 , methoxy and hydroxyl.27. The compound of wherein R claim 26 , R claim 26 , R claim 26 , and Rare independently selected from hydrogen claim 26 , alkyl claim 26 , substituted alkyl claim 26 , alkoxy claim 26 , substituted alkoxy claim 26 , halogen claim 26 , methyl claim 26 , methoxy and hydroxyl.28. The compound of wherein each Ris independently selected from ...

Подробнее
Номер записи: 64
07-07-2016 дата публикации

DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES

Номер: US20160193126A1
Автор: Jia Qi, Zhao Ji-Fu
Принадлежит:

The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier. 117-. (canceled)19. The compound of claim 18 , wherein the compound is 1-(2 claim 18 ,4-dihydroxyphenyl)-3-(3′ claim 18 ,4′-dihydroxyphenyl)-1-propanol claim 18 , 1-(2 claim 18 ,4-dihydroxyphenyl)-3-(3′ claim 18 ,4′-dimethoxyphenyl)-1-propanol claim 18 , 1-(2 claim 18 ,4-dihydroxyphenyl)-3-(2′-hydroxyphenyl)-1-propanol claim 18 , 1-(2 claim 18 ,4-dihydroxyphenyl)-3-(2′-methoxyphenyl)-1-propanol claim 18 , 1-(2 claim 18 ,4-dihydroxyphenyl)-3-(4′-methoxyphenyl)-1-propanol claim 18 , 1-(2 claim 18 ,4 claim 18 ,6-trihydroxyphenyl)-3-(4′-aminophenyl)-1-propanol claim 18 , 1-(2 claim 18 ,4-dihydroxyphenyl)-3-phenyl-1-propanol claim 18 , 1-(2 claim 18 ,4-dihydroxyphenyl)-3-(3′-methoxy-4′- ...

Подробнее
Номер записи: 65
15-07-2021 дата публикации

LONG WAVELENGTH EMITTING CHEMILUMINESCENT PROBES

Номер: US20210214607A1
Автор: Green Ori, Hananya Nir, IHSSEN Julian, Shabat Doron, Spitz Urs
Принадлежит:

Improved long wavelength-emitting chemiluminescent probes are easy to synthesize and are well-suited for both in vitro and in vivo applications, but are particularly well-suited for in vivo applications. The wavelengths of the emissions of the probes include those in the orange, red or NIR range. Dioxetane compounds and phenolic ester compounds are included. 121.-. (canceled)29. A composition comprising a compound according to and a carrier.30. A ready-to-use injectable solution comprising a compound according to .31. A method for determining the presence claim 22 , or measuring the level claim 22 , of an analyte in a sample claim 22 , the method comprising the following steps:{'claim-ref': {'@idref': 'CLM-00022', 'claim 22'}, '(a) contacting the sample with a compound according to , wherein upon exposure to said analyte, said compound reacts with said analyte thereby converting said compound into an emissive species; and'}(b) detecting the emission of said emissive species.32. A biomolecule characterized in that it is bound to a compound of as a label.33. The biomolecule of claim 32 , selected from the group consisting of an antibody claim 32 , a nucleic acid claim 32 , and a protein.34. The method of claim 31 , wherein the analyte is singlet oxygen claim 31 , and the compound is a compound of the Formula Ib.35. The method of claim 31 , wherein the sample is a biological sample.36. The method of claim 35 , wherein the biological sample is a bodily fluid claim 35 , a bodily-based solution claim 35 , or a tissue biopsy sample.37. The method of claim 31 , wherein the method is an in vitro method. The present invention relates to long wavelength emitting probes, in particular to compounds of Formulae Ia, Ib and II, and their applications.Optical imaging modalities have become powerful tools for noninvasive visualization of biomolecular systems and whole body (e.g. animals or human) in real-time with high spatial resolution. Moreover, imaging systems are relatively ...

Подробнее
Номер записи: 66
15-07-2021 дата публикации

Dioxetane compounds and their use for the detection of microorganisms

Номер: US20210214766A1
Автор: Chunyan Yao, Doron Shabat, Julian Ihssen, Lukas Wick, Michal Eli ROTH-KONFORTI, Nir HANANYA, Ori GREEN, Raffael VORBERG, Riccardo Cribiu, Urs Spitz, Zuzana BABJAKOVÀ
Принадлежит: Nemis Technologies Ag, Ramot at Tel Aviv University Ltd

Dioxetane compounds can be used in the detection of presence or absence, quantification and identification of microorganisms including bacteria, bacterial fragments (e.g., LPS, endotoxin), viruses, fungi as well as other pathogens by means of chemiluminescence and to corresponding methods. A method for the detection of a target analyte, a target microorganism or a target metabolite includes providing a medium including one or more target analytes, target microorganisms or target metabolites, adding a dioxetane compound to the medium so that the compound emits light, and detecting the emitted light.

Подробнее
Номер записи: 67
22-07-2021 дата публикации

ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY

Номер: US20210226253A1
Автор: NAGATA Yoshihide, Odani Toru
Принадлежит:

A lithium-ion secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution. The electrolytic solution includes a solvent, an electrolyte salt, and at least one of a first dioxane compound or a second dioxane compound. 2. The lithium-ion secondary battery according to claim 1 , whereinthe monovalent hydrocarbon group includes one of an alkyl group, an alkenyl group, and an alkynyl group, and has carbon number of less than or equal to 4, andthe divalent hydrocarbon group includes one of an alkylene group, an alkenylene group, and an alkynylene group, and has carbon number of less than or equal to 4.3. The lithium-ion secondary battery according to claim 1 , whereina content of the first dioxane compound in the electrolytic solution is from 0.001 weight percent to 5 weight percent, anda content of the second dioxane compound in the electrolytic solution is from 0.001 weight percent to 5 weight percent.4. The lithium-ion secondary battery according to claim 2 , whereina content of the first dioxane compound in the electrolytic solution is from 0.001 weight percent to 5 weight percent, anda content of the second dioxane compound in the electrolytic solution is from 0.001 weight percent to 5 weight percent.5. The lithium-ion secondary battery according to claim 1 , whereinthe solvent includes at least one of an unsaturated cyclic carbonate ester, a halogenated carbonate ester, or a dinitrile compound, and{'sub': 4', '2', '2', '4', '8, 'the electrolyte salt includes at least one of lithium tetrafluoroborate (LiBF), lithium difluorophosphate (LiPFO), or lithium bis(oxalato)borate (LiCBO).'}6. The lithium-ion secondary battery according to claim 2 , whereinthe solvent includes at least one of an unsaturated cyclic carbonate ester, a halogenated carbonate ester, or a dinitrile compound, and{'sub': 4', '2', '2', '4', '8, 'the electrolyte salt includes at least one of lithium tetrafluoroborate (LiBF), lithium difluorophosphate (LiPFO), or ...

Подробнее
Номер записи: 68
12-08-2021 дата публикации

Method for synthesis of lobaric acid and analog thereof

Номер: US20210246112A1
Автор: Hong Kum Lee, II-Chan KIM, Joung Han Yim, Jun Hyuck Lee, Kwon Joo YEO, Se Jong Han, Tai Kyoung Kim, Ui Joung Youn
Принадлежит: Korea Institute of Ocean Science and Technology KIOST

The present invention can synthesize lobaric acid and four analogues thereof, which are five phenolic lichen metabolites isolated from an extract of the Antarctic lichen Stereocaulon alpinum and selectively inhibit PTP1B, by a simple, economic and efficient chemical synthesis method.

Подробнее
Номер записи: 69
19-08-2021 дата публикации

SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN

Номер: US20210255545A1
Автор: ANRYU Yukako, ICHIKAWA Koji, MASUYAMA Tatsuro
Принадлежит: Sumitomo Chemical Company, Limited

Disclosed are a salt represented by formula (1), and an acid generator and a resist composition which include the same: 2. The salt according to claim 1 , wherein R claim 1 , Rand Reach independently represent a fluorine atom claim 1 , an iodine atom or a perfluoroalkyl group having 1 to 4 carbon atoms.3. An acid generator comprising the salt according to .4. A resist composition comprising the acid generator according to and a resin having an acid-labile group.7. The resist composition according to claim 4 , further comprising a salt generating an acid having an acidity lower than that of an acid generated from the acid generator.8. A method for producing a resist pattern claim 4 , which comprises:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, '(1) a step of applying the resist composition according to on a substrate,'}(2) a step of drying the applied composition to form a composition layer,(3) a step of exposing the composition layer,(4) a step of heating the exposed composition layer, and(5) a step of developing the heated composition layer. The present invention relates to a salt, an acid generator, a resist composition and a method for producing a resist pattern.Patent Document 1 mentions resist compositions each including, as acid generators, salts represented by the following formulas.Patent Document 2 mentions resist compositions including, as acid generators, salts represented by the following formulas.The present invention provides a salt and a resist composition comprising the salt capable of producing a resist pattern with CD uniformity (CDU) which is better than that of a resist pattern formed from the resist compositions including the salts mentioned above.The present invention includes the following inventions.[1] A salt represented by formula (I):wherein, in formula (I),Rrepresents a fluorine atom or a fluorinated alkyl group having 1 to 4 carbon atoms,R, Rand Reach independently represent a halogen atom, a fluorinated alkyl group having 1 to 4 ...

Подробнее
Номер записи: 70
18-08-2016 дата публикации

Compound, resin and photoresist composition

Номер: US20160237190A1
Автор: Koji Ichikawa, Tatsuro MASUYAMA, Yuki Suzuki
Принадлежит: Sumitomo Chemical Co Ltd

A compound represented by formula (I): wherein R 1 represents a hydrogen atom or a methyl group; R 2 represents a C1-C12 hydrocarbon group; X a and X b each independently represent an oxygen atom or a sulfur atom; X 11 represents a C1-C12 divalent saturated hydrocarbon group where a hydrogen atom can be replaced by a fluorine atom; and A 1 represents a C1-C12 divalent saturated hydrocarbon group or *-A 2 -X 1 -(A 3 -X 2 ) a -A 4 -, where * represents a binding site to an oxygen atom, A 2 , A 3 and A 4 each independently represent a C1-C12 divalent hydrocarbon group, X 1 and X 2 each independently represent —O—, —CO—O—, —O—CO— or —O—CO—O—, and “a” represents 0 or 1.

Подробнее
Номер записи: 71
17-08-2017 дата публикации

CYCLOOCTENES FOR BIOORTHOGONOL REACTIONS

Номер: US20170233365A1
Автор: HILDERBRAND Scott A., Varga Balazs R., Weissleder Ralph
Принадлежит:

This disclosure relates to trans-cyclooctene compounds and methods of using the same in bioorthogonal labeling experiments. 3. The compound of claim 1 , wherein Ris selected from H and Calkyl.4. The compound of claim 1 , wherein Ris an amine-reactive crosslinking group.5. The compound of claim 4 , wherein Ris an NHS carbamate.6. The compound of claim 5 , wherein the NHS carbamate is N claim 5 ,N′-disuccinimidyl carbonate.7. The compound of claim 1 , wherein n is 1.10. The compound of claim 9 , wherein Ris H.11. The compound of claim 9 , wherein Ris a Calkyl.12. The compound of claim 9 , wherein Ris an amine-reactive crosslinking group.13. The compound of claim 12 , wherein Ris an NHS carbamate.14. The compound of claim 13 , wherein the NHS carbamate is N claim 13 ,N′-disuccinimidyl carbonate.15. The compound of claim 9 , wherein n is 3.18. The compound of claim 17 , wherein Ris a H.19. The compound of claim 17 , wherein Ris an amine-reactive crosslinking group.20. The compound of claim 19 , wherein Ris an NHS carbamate.21. The compound of claim 20 , wherein the NHS carbamate is N claim 20 ,N′-disuccinimidyl carbonate.22. The compound of claim 17 , wherein n is 1.23. The compound of claim 17 , wherein m is 2. This application claims priority to U.S. Application Ser. No. 62/035,540, filed on Aug. 11, 2014, and 62/039,653, filed on Aug. 20, 2014, both of which are incorporated by reference in their entireties.This disclosure relates to trans-cyclooctene compounds and methods of using the same in bioorthogonal labeling experiments.The introduction of the tetrazine-based inverse electron demand Diels-Alder (iEDDA) reaction was a major breakthrough in bioorthogonal chemistry (see, e.g., Blackman, M. L. et al., 2008, 130, 13518-13519; and Devaraj, N. K. et al., 2008, 19, 2297-2299). The stability of the reaction partners and the excellent kinetics, in particular when employing trans-cyclooctene as the dienophile, has made these reagents a useful tool for bioorthogonal ...

Подробнее
Номер записи: 72
03-09-2015 дата публикации

PHOTORESIST COMPOSITION, COMPOUND AND PROCESS OF PRODUCING PHOTORESIST PATTERN

Номер: US20150248052A1
Автор: FUJITA Shingo, ICHIKAWA Koji, MASUYAMA Tatsuro
Принадлежит: Sumitomo Chemical Company, Limited

A photoresist composition comprising: 2. The photoresist composition according to wherein Ris a group represented by R—CO—O—* where * represents a binding site to I claim 1 , Rrepresents a C1-C22 hydrocarbon group in which a methylene group can be replaced by an oxygen atom or a carbonyl group and in which a hydrogen atom can be replaced by a hydroxyl group claim 1 , a halogen atom or a nitro group.3. The photoresist composition according to wherein Ris a C6-C24 aromatic hydrocarbon group in which a hydrogen atom can be replaced by a substituent.4. The photoresist composition according to which further comprises an onium carboxylic acid salt.7. A process for producing a photoresist pattern comprising the following steps (1) to (5):{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(1) a step of applying the photoresist composition according on a substrate,'}(2) a step of forming a composition film by conducting drying,(3) a step of exposing the composition film to radiation,(4) a step of baking the exposed composition film, and(5) a step of developing the baked composition film. This nonprovisional application claims priority under 35 U.S.C. §119(a) on Patent Application No. 2014-040138 filed in JAPAN on Mar. 3, 2014, the entire contents of which are hereby incorporated by reference.This disclosure relates to a photoresist composition, a compound and a process of producing photoresist pattern.A photoresist composition is used for semiconductor microfabrication employing a lithography process.US2012/028188A1 discloses a photoresist composition which comprises a resin having an acid-labile group, an acid generator, 2,6-diisopropylaniline and the compound represented as follow.The present invention relates to the followings:[1] A photoresist composition comprising: a resin having an acid-labile group, an acid generator, and a compound represented by formula (I):wherein R, Rand Reach independently represents a C1-C24 hydrocarbon group in which a hydrogen atom can be ...

Подробнее
Номер записи: 73
26-08-2021 дата публикации

CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN

Номер: US20210263416A1
Автор: ANRYU Yukako, ICHIKAWA Koji, MASUYAMA Tatsuro
Принадлежит: Sumitomo Chemical Company, Limited

Disclosed are a carboxylate represented by formula (I), and a carboxylic acid generator and a resist composition, including the same: 2. The carboxylate according to claim 1 , wherein R claim 1 , Rand Reach independently represent a fluorine atom claim 1 , an iodine atom or a perfluoroalkyl group having 1 to 4 carbon atoms.4. The carboxylate according to claim 3 , wherein Xis an alicyclic hydrocarbon group having 3 to 36 carbon atoms which may have a fluorine atom or a hydroxy group (—CH— included in the alicyclic hydrocarbon group may be replaced by —O— claim 3 , —S— claim 3 , —CO— or —SO—) claim 3 , a group obtained by combining an alicyclic hydrocarbon group having 3 to 36 carbon atoms with a chain hydrocarbon group having 1 to 18 carbon atoms (—CH— included in the alicyclic hydrocarbon group may be replaced by —O— claim 3 , —S— claim 3 , —CO— or —SO— claim 3 , —CH— included in the chain hydrocarbon group may be replaced by —O— or —CO— claim 3 , and the alicyclic hydrocarbon group and the chain hydrocarbon group may have a fluorine atom or a hydroxy group) claim 3 , an aromatic hydrocarbon group having 6 to 36 carbon atoms which may have a fluorine atom or a hydroxy group claim 3 , a group represented by formula (aa) or a group represented by formula (bb).5. A carboxylic acid generator comprising the carboxylate according to .6. A resist composition comprising the carboxylic acid generator according to claim 5 , an acid generator other than the carboxylic acid generator claim 5 , and a resin having an acid-labile group.9. A method for producing a resist pattern claim 5 , which comprises:{'claim-ref': {'@idref': 'CLM-00006', 'claim 6'}, '(1) a step of applying the resist composition according to on a substrate,'}(2) a step of drying the applied composition to form a composition layer,(3) a step of exposing the composition layer,(4) a step of heating the exposed composition layer, and(5) a step of developing the heated composition layer. The present invention ...

Подробнее
Номер записи: 74
06-11-2014 дата публикации

PRODUCTION OF CYCLIC ACETALS OR KETALS USING SOLID ACID CATALYSTS

Номер: US20140330029A1
Автор: Billodeaux Damon Ray, Howard Adam Scott, Little James Lon, McMurray Brian David, Terrill Daniel Latham
Принадлежит: EASTMAN CHEMICAL COMPANY

A process for making a cyclic compounds such as cyclic acetal or cyclic ketones by feeding aldehyde or ketone compounds and polyhydroxyl compounds to a reaction zone at a molar ratio of polyhydroxyl compounds to aldehyde or ketone compounds of at least 3:1, reacting these compounds in the presence of a solid acid such as an acidic ion exchange resin, to generate a liquid reaction mixture without separating water from the reaction mixture as it is being formed in the reaction mixture, withdrawing the liquid reaction mixture from the reaction zone as a liquid product stream, and feeding the liquid reaction product stream to a distillation column to separate cyclic acetal compounds from unreacted polyhydroxyl compounds, and optionally recycling back the unreacted polyhydroxyl compounds to the reaction zone. The process produces cyclic acetal compounds in yields of at least 90% with long catalyst life. The process is also suitable to make cyclic ketals from ketone compounds. 2. The liquid composition of claim 1 , comprising the following mole percentages:a) water: at least 3 mole % and up to 25 mole %;b) polyhydroxyl compounds: at least 50 mole % and up to 95 mole %;c) cyclic compounds: at least 3 mole % and up to 25 mole %.3. The liquid composition of claim 2 , comprising the following mole percentages:a) water: at least 9 mole % and up to 25 mole %;c) cyclic compounds: at least 9 mole % and up to 25 mole %.4. The liquid composition of claim 1 , comprising the following mole percentages:a) water: at least 12 mole % and up to 18 mole %;b) polyhydroxyl compounds: at least 70 mole % and up to 95 mole %;c) cyclic compounds: at least 12 mole % and up to 25 mole %.5. The liquid composition of claim 1 , wherein the cyclic compounds comprise cyclic acetals.6. The liquid composition of claim 1 , wherein the amount of any other liquid ingredient in the liquid composition does not exceed 8 mole %.7. The liquid composition of claim 6 , wherein the amount of any other liquid ...

Подробнее
Номер записи: 75
30-08-2018 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20180242582A1
Автор: Boebel Timothy A., Bravo-Altamirano Karla, Daeuble, Lu Yu, Meyer Kevin G., Nugent Benjamin M., SR. John F., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.48.-. (canceled)9. A composition for the control of a fungal pathogen including at least one of the compounds of and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 1 , a second fungicide claim 1 , an insecticide claim 1 , a nematocides claim 1 , a miticide claim 1 , an arthropodicide claim 1 , a bactericide.10. The composition for the control of a fungal pathogen according to claim 9 , wherein the at least one additional compound is at least one phytologically acceptable carrier material.11Mycosphaerella graminicolaSeptoria triticiPuccinia triticinaPuccinia striiformisVenturia inaequalisUstilago maydisUncinula necatorRhynchosporium secalisMagnaporthe griseaPhakopsora pachyrhiziLeptosphaeria nodorumBlumeria graministriticiBlumeria graminishordeiErysiphe cichoracearumGlomerella lagenariumCercospora beticolaAlternaria solaniPyrenophora teres. The compositions according to claim 9 , wherein the fungal pathogen is at least one pathogen selected from the group consisting of: Leaf Blotch of Wheat (; anamorph: ) claim 9 , Wheat Brown Rust () claim 9 , Stripe Rust () claim 9 , Scab of Apple () claim 9 , Blister Smut of Maize () claim 9 , Powdery Mildew of Grapevine () claim 9 , Barley Scald () claim 9 , Blast of Rice () claim 9 , Rust of Soybean () claim 9 , Glume Blotch of Wheat () claim 9 , Powdery Mildew of Wheat (f sp. ) claim 9 , Powdery Mildew of Barley (f. sp. ) claim 9 , Powdery Mildew of Cucurbits () claim 9 , Anthracnose of Cucurbits () claim 9 , Leaf Spot of Beet () claim 9 , Early Blight of Tomato () claim 9 , and Net Blotch of Barley ().12Septoria triticiPuccinia triticinaPhakopsora pachyrhizi. The composition according to wherein the fungal pathogen is ...

Подробнее
Номер записи: 76
30-07-2020 дата публикации

CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING

Номер: US20200237932A1
Автор: Eilon Tal, Green Ori, Hananya Nir, Satchi-Fainaro Ronit, Shabat Doron
Принадлежит:

The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging. 2. The compound of claim 1 , wherein:{'sup': '1', 'sub': 1', '8, '(i) Ris a linear or branched (C-C)alkyl; or'}{'sup': 2', '3, '(ii) Rand Rtogether with the carbon atom to which they are attached form a fused, spiro or bridged polycyclic ring; or'}{'sup': 5', '6, 'sub': 1', '8, '(iii) Rand Reach independently is (C-C)alkyl, and together with the oxygen atoms to which they are attached form a heterocyclic ring; or'}{'sup': 7', '8', '9', '7', '8', '9, 'sub': '2', '(iv) at least one of R, Rand Ris H, and the other of R, Rand Reach independently is an electron acceptor group selected from the group consisting of halogen, —NOand —CN; or'}{'sub': 3', '2', '3', '3', '3', '2', '2, '(v) said protecting group is selected from the group consisting of —CH, —CHOCH, —C(═O)C(CH), —CH—CH═CH, TBDMS, TBDPS, benzyl, and 2-nitro-4,5-dimethoxybenzyl.'}3. The compound of claim 2 , wherein Rand Rtogether with the carbon atom to which they are attached form adamantyl.4. The compound of claim 2 , wherein Rand Reach is isopropyl and together with the oxygen atoms to which they are attached form 4 claim 2 ,4 claim 2 ,5 claim 2 ,5-tetramethyl-1 claim 2 ,3 claim 2 ,2-dioxaborolanyl.5. The compound of claim 1 , wherein:{'sup': '1', 'sub': 1', '8, 'Ris a linear or branched (C-C)alkyl;'}{'sup': 2', '3, 'Rand Rtogether with the carbon atom to which they are attached form a fused, spiro or bridged polycyclic ring;'}{'sup': 5', '6, 'sub': 1', '8, 'Rand Reach independently is (C-C)alkyl, and together with the oxygen atoms to which they are attached form a heterocyclic ring; and'}{'sup': 7', '8', '9', '7', '8', '9, 'sub': '2', 'at least one of R, Rand Ris H, and the other of R, Rand Reach independently is an electron acceptor group ...

Подробнее
Номер записи: 77
06-08-2020 дата публикации

Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting

Номер: US20200247775A1
Автор: Arnaud Chevalier, Omar Khdour, Sidney Hecht, Yanmin Zhang
Принадлежит: Arizona Board of Regents of ASU

The present invention relates to the use of prodrugs susceptible to nitroreductase (NTR) activation. In particular, provided herein are mitochondria-targeting prodrug compounds and probes, including profluorescent near-infrared (NIR) probes and non-fluorescent prodrugs, as well as to methods of using said prodrug compounds and probes for imaging mitochondria and for mitochondria-specific delivery of therapeutic agents.

Подробнее
Номер записи: 78
01-10-2015 дата публикации

Highly active multidentate catalysts for efficient alkyne metathesis

Номер: US20150273457A1
Автор: Jyothish Kuthanapillil, Qi Wang, Wei Zhang
Принадлежит: University of Colorado

The invention relates to highly active and selective catalysts for alkyne metathesis. In one aspect, the invention includes a multidentate organic ligand wherein one substrate-binding site of the metal center is blocked. In another aspect, the invention includes N-quaternized or silane-based multidentate organic ligands, capable of binding to metals. In yet another aspect, the invention includes N-quaternized or silane-based multidentate catalysts. The catalysts of the invention show high robustness, strong resistance to small alkyne polymerization and significantly enhanced catalytic activity compared to their corresponding non-quaternized or non-silane-based multidentate catalyst analogues.

Подробнее
Номер записи: 79
01-10-2015 дата публикации

Biphenyl compounds for use in treating malaria and other parasitic disorders

Номер: US20150274637A1
Автор: Dietmar Manstein, Marcus Furch, Markus Kalesse, Matthias Preller, Nina Diaz-Gomez
Принадлежит: Leibniz Universitaet Hannover, MEDIZINISCHE HOCHSCHULE HANNOVER

The present invention relates to a compound of formula (I) as defined herein.

Подробнее
Номер записи: 80
22-09-2016 дата публикации

PROCESS FOR PREPARING CHLOROACETALDEHYDE ACETALS

Номер: US20160272610A1
Автор: DOERING Wolfgang, FLEISCHMANN Gerald, KRUEGER Benno, PETERSEN Hermann
Принадлежит:

The invention relates to a process for preparing chloroacetaldehyde acetals of monohydric, dihydric or higher-functionality aliphatic alcohols, in which the chloroacetaldehyde acetal is obtained from an aqueous chloroacetaldehyde solution in the presence of the alcohol to be acetalized and an acid catalyst by azeotropic removal of water with the aid of a solvent, wherein the solvent is a halogenated solvent. 1. A process for preparing a chloroacetaldehyde acetal of an aliphatic alcohol , wherein the chloroacetaldehyde acetal is obtained from an aqueous chloroacetaldehyde solution in a presence of the aliphatic alcohol to be acetalized and an acid catalyst by azeotropic removal of water with the aid of a solvent , wherein the solvent is a halogenated solvent.2. The process as claimed in claim 1 , wherein the halogenated solvent is a singly or multiply chlorinated or fluorinated hydrocarbon which has from one to five carbon atoms and forms an azeotrope having a boiling point in a range from 25° C. to 80° C. with water under atmospheric pressure.3. The process as claimed in claim 1 , wherein the halogenated solvent is trichloromethane.4. The process as claimed in claim 1 , wherein the aliphatic alcohol to be acetalized is a monohydric claim 1 , dihydric or higher-functionality aliphatic alcohol having from one to twelve carbon atoms.5. The process as claimed in claim 1 , wherein the acid catalyst is a member selected from the group consisting of an inorganic acid claim 1 , an organic acid and a strong acid ion exchange resin containing sulfonic acid groups.6. The process as claimed in claim 1 , wherein the acid catalyst is present in an amount of from 0.01 mol % to 2 mol % based on the chloroacetaldehyde used.7. The process as claimed in claim 2 , wherein the halogenated solvent is trichloromethane.8. The process as claimed in claim 7 , wherein the aliphatic alcohol to be acetalized is a monohydric claim 7 , dihydric or higher-functionality aliphatic alcohol having ...

Подробнее
Номер записи: 81
28-09-2017 дата публикации

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

Номер: US20170273303A1
Автор: Bravo-Altamirano Karla, Daeuble John F., DeKorver Kyle A., DeLorbe Johnathan E., Heemstra Ronald J., Meyer Kevin G., Yao Chenglin
Принадлежит:

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. The compound according to claim 1 , wherein X and Y are hydrogen.3. The compound according to claim 2 , wherein Ris alkyl or aryl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.4. The compound according to claim 2 , wherein Ris hydrogen or alkyl claim 2 , each optionally substituted with 0 claim 2 , 1 or multiple R.5. The compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.6. The compound according to claim 5 , wherein Ris alkyl or aryl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.7. The compound according to claim 5 , wherein Ris hydrogen or alkyl claim 5 , each optionally substituted with 0 claim 5 , 1 or multiple R.8. The compound according to claim 1 , wherein X is hydrogen and Y is Q.9. The compound according to claim 8 , wherein Ris alkyl or aryl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.10. The compound according to claim 8 , wherein Ris hydrogen or alkyl claim 8 , each optionally substituted with 0 claim 8 , 1 or multiple R.11. The compound according to claim 9 , wherein Ris hydrogen.12. The compound according to claim 9 , wherein Ris —C(O)R or —CHOC(O)R.13. The compound according to claim 12 , wherein Ris alkyl or alkoxy claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. The compound according to claim 13 , wherein Ris —CH claim 13 , —CH(CH) claim 13 , —CHOCHCH claim 13 , or —CHCHOCH.15. A composition for the control of a fungal pathogen including at least one of the compounds of Formula I and at least one additional compound selected from the group consisting of: a phytologically acceptable carrier material claim 13 , a second fungicide claim 13 , an insecticide claim 13 , a nematocide claim 13 , a miticide claim 13 , an arthropodicide claim 13 , and a bactericide.16. The composition according to claim 15 , wherein the least one ...

Подробнее
Номер записи: 82
11-11-2021 дата публикации

BENZAMIDE DERIVATIVES AS CGAS-STING PATHWAY AGONISTS

Номер: US20210347752A1
Автор: Chang Jinhong, Du Yanming, Guo Ju-Tao
Принадлежит:

Pharmaceutical compositions of the invention comprise functionalized benzamide derivatives useful as cyclic GMP-AMP synthase-Stimulator of interferon gene (cGAS-STING) pathway agonists, and useful for treating viral diseases and boost antitumor immunity. 14. A composition comprising an effective amount of at least one compound according to .15. The composition according to claim 14 , further comprising at least one excipient.16. A compound selected from the group consisting of:3,4-dimethoxy-N-(naphthalen-1-yl)benzamideN-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamideN-(naphthalen-1-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide3-methoxy-N-(naphthalen-1-yl)benzamide2-bromo-6-methoxy-N-(naphthalen-1-yl)benzamide2-bromo-N-(naphthalen-1-yl)benzamide6-bromo-N-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamideN-(naphthalen-1-yl)-3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-Carboxamide3,4-dimethoxy-N-(naphthalen-1-yl)benzamideN-(naphthalen-1-yl)benzamide2-chloro-N-(naphthalen-1-yl)benzamide4-fluoro-N-(naphthalen-1-yl)-2-(trifluoromethyl)benzamide2,4-difluoro-N-(naphthalen-1-yl)benzamide2-fluoro-N-(naphthalen-1-yl)-5-nitrobenzamide2-chloro-N-(naphthalen-1-yl)nicotinamide4-bromo-2-chloro-N-(naphthalen-1-yl)benzamide2-bromo-4,5-dimethoxy-N-(naphthalen-1-yl)benzamide2-bromo-4,5-difluoro-N-(naphthalen-1-yl)benzamide2-bromo-4-methoxy-N-(naphthalen-1-yl)benzamide6-bromo-N-(5,6,7,8-tetrahydronaphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-methyl-N-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2,3-dimethylphenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(3-cyano-2-fluorophenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2,3-dihydro-1H-inden-4-yl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(3-fluoro-2-methylphenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2-bromo-3-methylphenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2,3-dichlorophenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(2-fluorophenyl)benzo[d][1,3]dioxole-5-carboxamide6-bromo-N-(3- ...

Подробнее
Номер записи: 83
11-12-2014 дата публикации

METHOD AND DEVICE FOR THE SYNTHESIS OF ARTEMISININ

Номер: US20140364630A1
Автор: Kopetzki Daniel, Lévesque Francois, Seeberger Peter H.
Принадлежит: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC

The present invention is directed to a method for producing artemisinin having the formula 2. The method according to claim 1 , wherein all three steps i) claim 1 , ii) and iii) are performed in a continuous manner.3. The method according to claim 1 , wherein the photooxidation of step i) is carried out under pressure ranging from 1.5 bar to 15 bar.4. The method according to claim 1 , wherein all three steps i)-iii) are carried out under pressure.6. The method according to claim 1 , wherein the continuous flow reactor comprises a tube made of a fluorinated or perfluorinated alkylene polymer wherein the photooxidation of dihydroartemisinic acid takes place.7. The method according to claim 1 , wherein trifluoroacetic acid is used for the acid mediated cleavage.8. (canceled)9. A photochemical reactor for the production of artemisinin from dihydroartemisinic acid comprisinga light source,mixing device for mixing oxygen with a solution of dihydroartemisinic acid,reactor compartment exposed to the light source for irradiating the mixture of the solution of dihydroartemisinic acid and oxygen when the mixture passes the reactor compartment, anda back pressure regulator.10. The photochemical reactor according to claim 9 , wherein the reactor compartment is a tubing.11. The photochemical reactor according to claim 9 , wherein the mixing device is a T-mixer valve.12. The photochemical reactor according to further comprisinga box which is impervious to light with light reflecting inner walls and one opening through which the tubing enters the box and another opening through which the tubing leaves the box andmultiple loops of the tubing arranged in the inside of the box, wherein the tubing has an inlet for a mixture of dihydroartemisinic acid and oxygen on its one end before entering the box and an outlet for the reacted products on the opposite end after leaving the box.13. The photochemical reactor according to further comprisinga cooling liquid and a chiller.14. A continuous ...

Подробнее
Номер записи: 84
20-08-2020 дата публикации

Compounds for inhibiting bacterial growth via phosphatidylglycerol binding

Номер: US20200261415A1
Автор: Dennis H. Burns, Douglas S. English
Принадлежит: Wichita State University

Antibacterial small molecule compounds, termed liptins, bind to phosphatidylglycerol in bacterial plasma membranes. The small molecule compounds comprise a three-dimensional complementary binding pocket for phosphatidylglycerol, disrupting membrane function in a bacteriostatic or bactericidal manner. Methods of inhibiting bacterial growth and/or treating Gram-positive or Gram-negative bacterial infection using such compounds are also disclosed.

Подробнее
Номер записи: 85
26-09-2019 дата публикации

Chemiluminescent probes for diagnostics and in vivo imaging

Номер: US20190290787A1
Автор: Doron Shabat, Nir HANANYA, Ori GREEN, Ronit Satchi-Fainaro, Tal EILON
Принадлежит: Ramot at Tel Aviv University Ltd

Dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and π* acceptor group-containing dioxetane based chemiluminescence probes can be included in compositions. The chemiluminescence probes are useful for both diagnostics and in vivo imaging.

Подробнее
Номер записи: 86
26-09-2019 дата публикации

TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME

Номер: US20190292163A1
Автор: BECKER Cyrus K., Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит:

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used. 170-. (canceled)72. The compound of claim 71 , wherein Ris Pand Ris H.73. The compound of claim 71 , wherein Ris H and Ris P.74. The compound of claim 71 , wherein Ris Pand Ris P.75. The compound of claim 71 , wherein each of Rto Ris H.76. The compound of claim 71 , wherein at least one of Rto Ris deuterium.77. The compound of claim 71 , wherein Z is —OR.78. The compound of claim 71 , wherein Z is P.79. The compound of claim 71 , wherein Z is —N(R)R.80. The compound of claim 71 , wherein Z is —OH.82. A composition comprising a compound of or a pharmaceutically acceptable salt thereof and at least one other component.83. The composition of claim 82 , which is formulated for transdermal delivery.84. The composition of claim 83 , which is formulated for transdermal delivery with a patch.85. The composition of claim 82 , further comprising at least one solvent.86. A method of treating pulmonary hypertension claim 71 , comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.87. The method of claim 86 , wherein the pulmonary hypertension is pulmonary arterial hypertension.88. The method of claim 86 , wherein the compound is administered transdermally.89. The method of claim 88 , wherein the compound is administered via a transdermal patch. This application claims priority to U.S. provisional application 61/751,608 filed Jan. 11, 2013 which is incorporated herein by reference in its entirety for all purposes.Pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) is a disease which can result in death and is ...

Подробнее
Номер записи: 87
27-10-2016 дата публикации

Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain

Номер: US20160311792A1
Автор: Choi Yong Moon
Принадлежит:

The present invention relates to sulfamate derivative compounds and a composition for treating and/or alleviating pain containing the sulfamate derivative compounds or a pharmaceutically acceptable salt thereof as an active ingredient. More specifically the present invention relates to a pharmaceutical composition for treating or alleviating pain containing a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or alleviation of pain comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or alleviation of pain. 2. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein X is H claim 1 , OMe claim 1 , F claim 1 , or I; and n is an integer from 1-4.3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein l or m are each independently an integer 0 or 1.4. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Rand Rare each independently methyl claim 1 , ethyl claim 1 , isopropyl or Rand Rtogether with the carbon atom to which they attach form a cyclopentyl or a cyclohexyl group.5. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein Rand Rare each independently hydrogen or methyl.6. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , whereinX is chlorine, fluorine, iodine, bromine, methoxy or H;n is an integer from 1-4;{'sup': 1', '2, 'sub': 1', '2, 'Rand Rare each dependently selected from the group consisting of methyl, ethyl and isopropyl, or Rand Rtogether with the carbon atom to which they attach form a cyclopentyl or a cyclohexyl ring;'}{'sup': 3', '4, 'Rand Rare each dependently selected from the group consisting of H, methyl, ethyl, and isopropyl;'}l and m are each dependently an integer ...

Подробнее
Номер записи: 88
18-10-2018 дата публикации

In Situ Chemiluminescent Substrates and Assays

Номер: US20180299456A1
Автор: Gee Melissa, Sparks Alison, Wang Zhixian
Принадлежит:

Methods for generating a chemiluminescent enzyme substrate in situ, in aqueous or other assay conditions. Also disclosed are methods to use the substrates to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Kits relating to these methods are also disclosed. 2. The method of claim 1 , wherein the oxidant is selected from hydrogen peroxide claim 1 , sodium molybdate claim 1 , hydrogen peroxide and sodium molybdate claim 1 , hypochlorite claim 1 , hypochlorite and hydrogen peroxide claim 1 , aryl endoperoxide claim 1 , calcium peroxide peroxyhydrate claim 1 , and combinations thereof.3. The method of claim 2 , wherein the oxidant is hydrogen peroxide claim 2 , and hydrogen peroxide and sodium molybdate.6. The method of claim 1 , wherein Ris alkyl containing 1 to 2 carbon atoms or trifluoalkyl containing 1 to 2 carbon atoms.12. The method of claim 1 , wherein the enzyme moiety comprises a hydrolytic enzyme.13. The method of claim 12 , wherein the hydrolyic enzyme is alkaline phosphatase claim 12 , β-galactosidase claim 12 , β-glucosidase claim 12 , β-glucuronidase claim 12 , or neuraminidase.14. The method of claim 13 , wherein the enzyme moiety is an enzyme.15. The method of claim 14 , further comprising the step of detecting the light emitted from the reaction mixture after addition of the aqueous solution of the 1 claim 14 ,2-dioxetane enzyme substrate claim 14 , wherein the emission of light is indicative of the presence of the enzyme claim 14 , and the amount of light emitted can be correlated to the amount of the enzyme present in the sample.16. The method of claim 13 , wherein the enzyme moiety is an enzyme-linked antibody comprising a first antibody capable of binding to an antigen and an enzyme capable of cleaving the 1 claim 13 ,2-dioxetane enzyme substrate so that the substrate decomposes and generates light.17. The method of claim 16 , wherein the first antibody is covalently or non-covalently linked to the enzyme.18. The ...

Подробнее
Номер записи: 89
03-11-2016 дата публикации

BROMINE-SENSITIZED SOLAR PHOTOLYSIS OF CARBON DIOXIDE

Номер: US20160319423A1
Автор: BRAIMAN Mark S.
Принадлежит:

There is described a process for depositing carbon on a surface, comprising, while contacting a mixture of COand Brwith a polar substrate presenting apposed surfaces, exposing a sufficient area of said mixture in the region of said apposed surfaces to light of sufficient intensity and frequency to result in deposition of carbon on at least some of said apposed surfaces. Other embodiments are also described. 119-. (canceled)20. A composition of matter comprising a polar substrate presenting apposed surfaces and a mixture of COand Brin contact with at least some of said apposed surfaces.21. A composition of matter according to claim 20 , wherein said polar substrate is a non-carbonaceous polar substrate.22. A composition of matter according to claim 21 , wherein said polar substrate is selected from the group consisting of silica claim 21 , silica-based glasses claim 21 , alumina and titania claim 21 , and mixtures thereof.23. A composition of matter according to claim 22 , wherein said polar substrate is in particulate form.24. A composition of matter according to claim 22 , wherein said polar substrate is selected from sand claim 22 , silica gel claim 22 , powdered alumina claim 22 , titania claim 22 , quartz sand claim 22 , glass spheres claim 22 , and glass wool.25. A composition of matter according to claim 20 , wherein the polar substrate claim 20 , COand Brand are contained in a UV and visible-light transparent region of a reaction vessel.26. A composition of matter according to claim 25 , wherein said UV and visible-light transparent region is transparent to light having a wavelength of 300 to 500 nm.27. A composition of matter according to claim 25 , wherein said UV-light transparent region is also transparent to visible light.28. A composition of matter according to any of wherein the reaction vessel is made from quartz or borosilicate glass.2937-. (canceled)38. A reactor for utilizing solar energy and bromine to reduce CO claim 25 , the reactor comprising a ...

Подробнее
Номер записи: 90
12-11-2015 дата публикации

LOW CATALYST LOADING IN METATHESIS REACTIONS

Номер: US20150322079A1
Автор: Kadyrov Renat
Принадлежит: Evonik Industries AG

The present invention relates to a method for producing metathesis products comprising contacting metathesis starting materials under metathesis conditions with a metathesis catalyst, wherein the metathesis catalyst is employed in an amount of from 0.0001 mol-% to 1 mol-% based on half of the sum of the reactive double bonds of the metathesis starting materials and wherein the ethylene or propylene generated in the course of the reaction is removed from the reaction mixture. 1. Method for producing metathesis products comprising contacting metathesis starting materials under metathesis conditions with a metathesis catalyst , wherein the metathesis catalyst is employed in an amount of from 0.0001 mol-% to 1 mol-% based on half of the sum of the reactive double bonds of the metathesis starting materials and wherein the ethylene or propylene generated in the course of the reaction is removed from the reaction mixture.3. Method according to claim 2 , wherein the metathesis catalyst is a ruthenium catalyst of general formula 3.5. Method according to claim 1 , wherein ethylene or propylene are removed from the reaction mixture by volatilization.6. Method according to claim 5 , wherein the reaction mixture is sparged with inert gas to remove ethylene or propylene.7. Method according to claim 6 , wherein the reaction mixture is continuously sparged with inert gas to remove ethylene or propylene.8. Method according to claim 1 , wherein the metathesis starting materials are olefinic compounds having at least one reactive double bond in the form of an α-olefin and/or β-olefin claim 1 , with the proviso that not more than one β-olefin is present in the same molecule.9. Method according to claim 1 , wherein the metathesis starting material is an olefinic compound having two reactive double bonds in the form of two α-olefins or one α-olefin and one β-olefin.10. Method according to claim 1 , wherein the metathesis starting materials are olefinic compounds having at least one ...

Подробнее
Номер записи: 91
10-10-2019 дата публикации

LIGHT GENERATING MICROCAPSULES FOR SELF-HEALING POLYMER APPLICATIONS

Номер: US20190309105A1
Автор: Campbell Eric J., Czaplewski-Campbell Sarah K., Kuczynski Joseph, Tofil Timothy J.
Принадлежит:

A self-healing polymeric material includes a polymeric matrix material, wherein dispersed within the polymeric matrix material is a mixture of materials that includes monomers and a photoinitiator, and a plurality of light generating microcapsules dispersed in the polymeric matrix material. Each light generating microcapsule encapsulates multiple reactants that undergo a chemiluminescent reaction. The chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator. 1. A self-healing polymeric material comprising:a polymeric matrix material;wherein dispersed within the polymeric matrix material is a mixture of materials that includes monomers and a photoinitiator; anda plurality of light generating microcapsules dispersed in the polymeric matrix material, each light generating microcapsule of the plurality of light generating microcapsules encapsulating multiple reactants that undergo a chemiluminescent reaction, wherein each light generating microcapsule comprises an outer shell and an inner shell,wherein the chemiluminescent reaction generates a photon having a wavelength within a particular emission range that is consistent with an absorption range of the photoinitiator and wherein the chemiluminescent reaction occurs without rupture of the outer shell of the light generating microcapsules.2. The self-healing polymeric material of claim 1 , wherein a crack in the polymeric matrix material causes migration of the monomers and photoinitiator into the crack.3. The self-healing polymeric material of claim 2 , wherein further propagation of the crack in the polymeric matrix material results in application of a compressive force to a light generating microcapsule of the plurality of light generating microcapsules claim 2 , the compressive force triggering the chemiluminescent reaction within the light generating microcapsule.4. The self-healing polymeric material of ...

Подробнее
Номер записи: 92
09-11-2017 дата публикации

Flash and Glow 1,2-Dioxetanes

Номер: US20170321245A1
Автор: Edwards Brooks, Mihali Albana, Wang Zhixian
Принадлежит:

Compounds having chemiluminescent flash and glow properties. Also disclosed are methods using the compounds to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Also disclosed are kits relating to these compounds. 193.-. (canceled)951. The compound of claim , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 37° C. which reaches a maximum in less than about 5 minutes.961. The compound of claim , wherein the cleavage of the bond cleavable by an enzyme moiety results in the generation of light at 37° C. which reaches a maximum in 3 minutes or less.100. A method for generating light , comprising the steps of:{'b': '1', '(a) providing a compound of claim ;'}(b) providing an enzyme complex comprising an enzyme moiety which is capable of cleaving the compound;(c) contacting the enzyme complex with the compound to form a reaction mixture; and,(d) allowing the reaction mixture to generate light.101. The method of claim 100 , wherein the cleavage of the bond cleavable by the enzyme moiety results in the generation of light at 37° C. which reaches a maximum in 3 minutes or less.105. The method of claim 100 , wherein the compound has a constant signal-to-noise ratio.106. The method of claim 100 , wherein the compound has improved sensitivity claim 100 , wherein sensitivity is defined as the lowest amount of hIL-6 detect at a signal-to-noise of 2.107. The method of claim 100 , wherein the enzyme moiety is a hydrolytic enzyme chosen from alkaline phosphatase claim 100 , β-galactosidase claim 100 , β-glucosidase claim 100 , β-glucuronidase claim 100 , or neuraminidase.108. A method for determining the presence and/or amount of an enzyme in a sample claim 100 , comprising the steps of:{'b': '1', '(a) providing a compound of claim ;'}(b) providing a sample suspected of comprising the enzyme which is capable of cleaving the compound so that it decomposes and generates light;(c) contacting the sample ...

Подробнее
Номер записи: 93
08-10-2020 дата публикации

SULFONIUM COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS

Номер: US20200319550A1
Автор: FUKUSHIMA Masahiro, Katayama Kazuhiro, Kera Yuki, OHASHI Masaki
Принадлежит: SHIN-ETSU CHEMICAL CO., LTD.

A novel sulfonium compound of formula (A) and a chemically amplified resist composition comprising the same as a PAG are provided. When processed by photolithography using KrF or ArF excimer laser, EB or EUV, the resist composition has a high sensitivity and reduced acid diffusion and is improved in lithography properties. 5. A photoacid generator comprising the sulfonium compound of .9. The resist composition of claim 6 , further comprising an organic solvent.10. The resist composition of claim 6 , further comprising another photoacid generator other than the photoacid generator.13. The resist composition of claim 6 , further comprising an amine compound.14. The resist composition of claim 6 , further comprising a surfactant which is insoluble or substantially insoluble in water and soluble in alkaline developer claim 6 , and/or a surfactant which is insoluble or substantially insoluble in water and alkaline developer.15. A pattern forming process comprising the steps of applying the chemically amplified resist composition of to form a resist film on a substrate claim 6 , exposing a selected region of the resist film to KrF excimer laser claim 6 , ArF excimer laser claim 6 , EB or EUV claim 6 , and developing the exposed resist film in a developer.16. The pattern forming process of wherein the developing step uses an alkaline aqueous solution as the developer claim 15 , thereby forming a positive pattern in which an exposed region of the resist film is dissolved away and an unexposed region of the resist film is not dissolved.17. The pattern forming process of wherein the developing step uses an organic solvent as the developer claim 15 , thereby forming a negative pattern in which an unexposed region of the resist film is dissolved away and an exposed region of the resist film is not dissolved.18. The pattern forming process of wherein the organic solvent is at least one solvent selected from the group consisting of 2-octanone claim 17 , 2-nonanone claim 17 , 2- ...

Подробнее
Номер записи: 94
23-11-2017 дата публикации

Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases

Номер: US20170334908A1
Автор: Chongxi Yu, Lina Xu
Принадлежит: Techfields Pharma Co Ltd

One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Подробнее
Номер записи: 95
23-11-2017 дата публикации

Macrocyclic picolinamides as fungicides

Номер: US20170334934A1
Автор: Daeuble, DeKorver Kyle A., DeLorbe Johnathan E., Meyer Kevin G., SR. John F., WILMONT Jeremy, Yao Chenglin
Принадлежит: DOW AGROSCIENCES LLC

This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides. 2. A compound according to claim 1 , wherein X and Y are hydrogen.3. A compound according to claim 2 , wherein Ris alkyl claim 2 , aryl claim 2 , or acyl each optionally substituted with 0 claim 2 , 1 or multiple R.4. A compound according to claim 2 , wherein Ris chosen from —(CH)Rwhere n is an integer between 0 and 4 and Ris hydrogen or alkyl claim 2 , optionally substituted with 0 claim 2 , 1 or multiple R.5. A compound according to claim 1 , wherein X is C(O)Rand Y is hydrogen.6. A compound according to claim 5 , wherein Ris chosen from hydrogen claim 5 , alkyl claim 5 , aryl claim 5 , acyl claim 5 , or silyl each optionally substituted with 0 claim 5 , 1 or multiple R.7. A compound according to claim 5 , wherein Ris chosen from —(CH)Rwhere n is an integer between 0 and 4 and Ris hydrogen or alkyl claim 5 , optionally substituted with 0 claim 5 , 1 or multiple R.8. A compound according to claim 1 , wherein X is hydrogen and Y is Q.9. A compound according to claim 8 , wherein Ris chosen from alkyl claim 8 , aryl claim 8 , or acyl each optionally substituted with 0 claim 8 , 1 or multiple R.10. A compound according to claim 8 , wherein Ris chosen from —(CH)Rwhere n is an integer between 0 and 4 and Ris hydrogen or alkyl claim 8 , optionally substituted with 0 claim 8 , 1 or multiple R.11. A compound according to and claim 8 , wherein Ris hydrogen.12. A compound according to and claim 8 , wherein Ris —C(O)Ror —CHOC(O)R.13. A compound according to claim 12 , wherein Ris chosen from alkyl or alkoxy claim 12 , each optionally substituted with 0 claim 12 , 1 claim 12 , or multiple R.14. A compound according to claim 13 , wherein Ris chosen from —CHor —CH(CH).15. A composition for the control of a fungal pathogen including at least one of the compounds of - and a phytologically acceptable carrier material.16. A composition for the control of a fungal pathogen including mixtures ...

Подробнее
Номер записи: 96
30-11-2017 дата публикации

NOVEL ACETALS OF 1-(3,3-DIMETHYLCYCLOHEX-1-ENYL) ETHANONE, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME IN PERFUMERY

Номер: US20170342343A1
Автор: MAHAIM Cyril, Muratore Agnés
Принадлежит:

The present invention concerns new fragrant compounds exhibiting animal or amber notes, without any woody aspect. More particularly, new acetal derivatives of 1-(3,3-dimethylcyclohex-1-enyl)ethanone are disclosed, which correspond to the following general formula I: 2. The compound according to claim 1 , wherein said carbon-carbon bond shown as a dotted line is absent.3. The compound according to claim 1 , wherein n is 0 and m is 1.4. The compound according to claim 1 , wherein n and m are 0.5. The compound according to claim 1 , wherein Rand Rrepresent a saturated C-Calkyl group.6. The compound according to claim 1 , said compound being chosen from 2-(3 claim 1 ,3-dimethylcyclohex-1-enyl)-2-methyl-1 claim 1 ,3-dioxolane claim 1 , 2-(3 claim 1 ,3-dimethylcyclohex-1-enyl)-2 claim 1 ,4-dimethyl-1 claim 1 ,3-dioxolane claim 1 , 2-(3 claim 1 ,3-dimethylcyclohex-1-enyl)-2-methyl-1 claim 1 ,3-dioxane claim 1 , 2-(3 claim 1 ,3-dimethylcyclohex-1-enyl)-2 claim 1 ,5-dimethyl-1 claim 1 ,3-dioxane claim 1 , 2-(3 claim 1 ,3-dimethylcyclohex-1-enyl)-2 claim 1 ,5 claim 1 ,5-trimethyl-1 claim 1 ,3-dioxane claim 1 , 2-(3 claim 1 ,3-dimethylcyclohex-1-enyl)-5 claim 1 ,5-diethyl-2-methyl-1 claim 1 ,3-dioxane and 2-(3 claim 1 ,3-dimethylcyclohex-1-enyl)-2-methyl-4 claim 1 ,7-dihydro-1 claim 1 ,3-dioxepine.8. The composition according to claim 7 , said composition comprising at least one compound chosen from 2-(3 claim 7 ,3-dimethylcyclohex-1-enyl)-2-methyl-1 claim 7 ,3-dioxolane claim 7 , 2-(3 claim 7 ,3-dimethylcyclohex-1-enyl)-2 claim 7 ,4-dimethyl-1 claim 7 ,3-dioxolane claim 7 , 2-(3 claim 7 ,3-dimethylcyclohex-1-enyl)-2-methyl-1 claim 7 ,3-dioxane claim 7 , 2-(3 claim 7 ,3-dimethylcyclohex-1-enyl)-2 claim 7 ,5-dimethyl-1 claim 7 ,3-dioxane claim 7 , 2-(3 claim 7 ,3-dimethylcyclohex-1-enyl)-2 claim 7 ,5 claim 7 ,5-trimethyl-1 claim 7 ,3-dioxane claim 7 , 2-(3 claim 7 ,3-dimethylcyclohex-1-enyl)-5 claim 7 ,5-diethyl-2-methyl-1 claim 7 ,3-dioxane and 2-(3 claim 7 ,3-dimethylcyclohex ...

Подробнее
Номер записи: 97
31-10-2019 дата публикации

Prodrug and profluorescent compounds for selective mitochondrial imaging and therapeutic targeting

Номер: US20190330176A1
Автор: Amaud CHEVALIER, Omar Khdour, Sindey HECHT, Yanmin Zhang
Принадлежит: Arizona Board of Regents of ASU

The present invention relates to the use of prodrugs susceptible to nitroreductase (NTR) activation. In particular, provided herein are mitochondria-targeting prodrug compounds and probes, including profluore scent near-infrared (NIR) probes and non-fluorescent prodrugs, as well as to methods of using said prodrug compounds and probes for imaging mitochondria and for mitochondria-specific delivery of therapeutic agents.

Подробнее
Номер записи: 98
07-12-2017 дата публикации

CONDENSED HETEROCYCLIC COMPOUND

Номер: US20170349605A1
Автор: BANNO Yoshihiro, Fukuda Koichiro, IKEDA Zenichi, KAKEGAWA Keiko, KAMAURA Masahiro, KIKUCHI Fumiaki, NISHIKAWA Yoichi, SASAKI Minoru, Sasaki Shigekazu, Takami Kazuaki
Принадлежит: Takeda Pharmaceutical Company Limited

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]. 2. The compound according to or a salt thereof claim 1 , wherein [ 1) a halogen atom,', '2) a carboxy group,', '3) a cyano group,', {'sub': 6-14', '1-6', '1-6, '4) a carbamoyl group optionally substituted by a Caryl group optionally substituted by 1 to 3 substituents selected from a sulfo group; and a Calkyl group optionally substituted by a mono- or di-Calkylphosphono group,'}, {'sub': '1-6', '5) 3- to 14-membered nonaromatic heterocyclylcarbonyl optionally substituted by 1 to 3 substituents selected from a carboxy group; and/or a mono- or di-Calkyl-carbamoyl group substituted by 1 or 2 carboxy groups,'}, {'sub': '1-6', '6) a 3- to 14-membered nonaromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from a Calkyl group substituted by 1 or 2 carboxy groups; and a carboxy group,'}, {'sub': 1-6', '1-6', '1-6, '7) a Calkyl group optionally substituted by 1 to 3 substituents selected from a mono- or di-Calkyl-carbamoyl group substituted by 1 to 3 substituents selected from a carboxy group, a hydroxy-phenyl group, and a carbamoyl group; a Calkoxy-carbonyl group; and a carboxy group,'}, {'sub': 1-6', '1-6, '8) a Calkoxy group optionally substituted by a mono- or di-Calkyl-carbamoyl group substituted by 1 or 2 carboxy groups,'}, {'sub': '1-6', 'claim-text': (a) a carboxy group;', '(b) a sulfo group;', '(c) a hydroxy group;', {'sub': '1-6', '(d) a Calkoxy group optionally substituted by a phenyl group;'}, {'sub': '1-6', '(e) a Calkoxy-carbonyl group;'}, '(f) a guanidino group;', {'sub': '6-14 ...

Подробнее
Номер записи: 99
07-11-2019 дата публикации

Organic Materials with Special Optical Effects

Номер: US20190337885A1
Автор: Grégory Dupeyre, Laurélie Poulard, Philippe Laine
Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Universite Paris Diderot Paris 7

The present invention relates to a compound of the following formula (I). The invention also relates to uses thereof as a chromophore as such or for building pigments displaying special optical effects, including metal-like reflection.

Подробнее
Номер записи: 100